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Risk factors associated with six-month mortality following vascular surgery
Jamila Khatoon Adam, Bruce Biccard, Sumansha Nepaul and Wafaa N.S. Rmaih
Durban University of Technology, Department of Biomedical and Clinical Technology, Durban, KwaZulu-Natal, South Africa
Introduction: Every day a large number of patients undergo vascular surgery, but not all of these patients survive surgery. By looking at risk 
factors identifi ed in previous studies the outcome of some patients’ surgery may be predicted. However, there is a limited number of studies 
on South African patients with regards to risk factors associated with post-operative vascular surgical survival. The aim of this study was to 
identify risk factors associated with six-month mortality following vascular surgery. 
Methods: Patients selected (>39y) for this study were scheduled for both elective and emergency vascular surgery at Inkosi Albert Luthuli 
Central Hospital, between June 2003 and July 2007. Demographic data from the hospital computerised data base was extracted, as well 
as patients’ date of surgery and their inpatient and outpatient visit dates. The patients’ hospital visits following surgery were analysed. 
283 patients were included. The risk factors examined in this study were; male sex, history of smoking, ischaemic heart disease, congestive 
cardiac failure; cerebrovascular accident, diabetes, hypertension, creatinine >180 μmol.L-1, chronic beta-blockade, major vascular surgery, 
mean daily heart rate (HR) the day before surgery; mean daily HR on the third postoperative day and mean daily systolic blood pressure (SBP) 
< 100 or > 179mmHg. 
These factors were entered into a bivariate cox regression analysis. Risk factors with a p < 0.1 were entered into a multivariate analysis. 
We defi ned mortality as those patients that did not survive six months post surgery.
Results: There were 21 intermediate-term non-survivors and 262 survivors. Two risk factors, hypertension and diabetes were entered into 
a multivariate analysis. Hypertension had a hazard ratio of 3.59 (95% Confi dence Interval (CI) 0.83-15.4, p=0.09) and diabetes had a 
hazard ratio of 2.28 (95% Confi dence Interval (CI) 0.94-5.52, p=007).
Conclusion: Diabetes and hypertension were bivariate predictors of intermediate term mortality following vascular surgery.
The anti-aging factor Sirtuin 1: a possible role in cardioprotection?
T. Adam, L.H. Opie and S. Lecour
Hatter Cardiovascular Research Institute, Faculty of Health Sciences, University of Cape Town, South Africa
Introduction: Ischaemic preconditioning (IPC) is a process whereby brief episodes of alternating ischaemia and reperfusion prior to a prolonged 
lethal episode of ischaemia-reperfusion can reduce myocardial damage. However, the mechanisms mediating this cardioprotective effect 
remain unclear. Sirtuin 1 (Sirt1) is a nicotinamide adenine dinucleotide-dependent class III histone deacetylase which regulates a myriad of 
cellular processes including anti-aging. Sirtuins can protect the heart by enhancing cardiomyocyte survival and oxidative stress resistance, as 
well as by preventing increases in cardiac hypertrophy, fi brosis and ventricular dysfunction associated with aging. We propose that Sirt1 
activation plays a role in IPC-mediated cardioprotection. 
Methods: Cultured C2C12 mouse skeletal muscle myotubes were preconditioned for 30 mins by exposure to hypoxia, or by pretreatment 
with the potent sirtuin activator resveratrol (RSV). Subsequent to a 1 hour washout period, cells were subjected to a simulated ischaemic
 insult for 8 hours. To investigate whether Sirt1 is involved in IPC, 50 M or 50 mM of nicotinamide (NAM), a sirtuin inhibitor, was given during 
the IPC stimulus. Cell viability was assessed at the end of sustained simulated ischaemia using the trypan blue exclusion test. In addition, 
Sirt1 deacetylase activity was measured after 30 mins of IPC.
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Results: IPC increased cell viability to 61.91.7% (p<0.001 compared to the simulated ischaemic control: 47.11.9%). Similarly, RSV treatment 
mimicked IPC, improving cell viability to 69.32.9%. Incubation of C2C12 myotubes with both concentrations of NAM did not abolish 
the protective effect of IPC. Sirt1 deacetylase activity measured after IPC was similar to control cells (0.390.09 AU for IPC versus 0.420.08 
AU for control cells).
Conclusion: These data suggest that cardioprotection by IPC is independent of Sirt1 activation.
An unusual case of endomyocardial fi brosis in a 2 year old child
P.E. Adams, G. Dumani, H. Ntsinjana and A.M. Cilliers
Division of Paediatric Cardiology, Department of Paediatrics and Child Health, Chris Hani Baragwanath Hospital, University of the Witwaters-
rand, Johannesburg, South Africa
 
Introduction: Endomyocardial fi brosis accounts for a signifi cant proportion of cardiovascular presentations of children in endemic areas. 
The cause of this cardiomyopathy remains elusive. However, this case strongly suggests a genetic aetiology.
Case description: We present a one year nine month old male child who was admitted with a cough and generalised body swelling for two 
days. He was described as previously well, with a single previous admission for pneumonia. He was born in South Africa of a Mozambican 
father and a South African mother. He has never travelled to Mozambique. On admission to Chris Hani Baragwanath Hospital he was 
diagnosed with a large pericardial effusion and anasarca. 
Emergency treatment included pericardial drainage and institution of TB treatment. The effusion persisted despite TB treatment. Initial 
results were not suggestive of TB. Investigations for other possible causes of the effusion were unhelpful. Of note, there was no eosinophilia. 
The echocardiogram showed markedly dilated atria, an aneurysm arising from the RV and features of restrictive cardiomyopathy. A 
cardiac catheterisation was undertaken. The haemodynamic data showed restrictive physiology of both ventricles and a myocardial biopsy 
confi rmed the diagnosis of endomyocardial fi brosis.
Discussion: Endomyocardial fi brosis is the most common cause of restrictive cardiomyopathy. In endemic areas of Africa such as 
Mozambique it has been associated with 20% of all heart failure (Mocumbi et al). The aetiology remains unknown.  The study patient is most 
unusual in presenting at such a young age. The only apparent connection to an endemic area is a possible genetic link by virtue of his father 
being Mozambican. 
Conclusion: The diagnosis of endomyocardial fi brosis should be excluded in all age groups presenting with a restrictive cardiomyopathy. 
A genetic aetiology is likely but needs further elucidation.
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A review of Takotsubo cardiomyopathy in Johannesburg
G. Angel, P. Manga, N. Patel, M. Allison and R. Lamparelli
Division of Cardiology, CM Johannesburg Academic Hospital, University of Witwatersrand and Milpark & Sunninghill Hospitals, Johannesburg, 
South Africa
 
Background & aims: Takotsubo cardiomyopathy mimics acute coronary syndrome and is accompanied by reversible left ventricular apical 
ballooning in the absence of angiographically signifi cant coronary artery disease. Takotsubo cardiomyopathy is relatively uncommon but 
increasingly recognised. The aims of this study was to assess the patient demographics, precipitating events and outcomes in a series of 
patients diagnosed with Takotsubo cardiomyopathy in the Johannesburg metropolitan area, and to compare them to other reported series 
with the same condition. 
Methods: We retrospectively studied seven patients diagnosed with Takotsubo cardiomyopathy from 2005-2009. Cardiac biomarkers, 
ECGs, transthoracic echocardiography and coronary and left ventricular angiography was performed in all the patients. 
Results: The mean age of the patients was 60 years. All 7 (100%) patients had a specifi c precipitating stressful event just prior to the episode 
of chest pain. All patients were female, with equal representation across all the racial groups. All were found to have normal coronary 
arteries. 6 patients had the classic apical ballooning on left ventriculography, whilst one had sparing of the apex but ballooning of the base. 
Follow up examinations as well as echocardiography or LV angiography confi rmed full resolution of the LV dysfunction in 85% (6/7) of the 
patients as well as full clinical recovery. One patient died of complications secondary to cancer prior to follow up echocardiography or 
LV angiography. 14% (1/7) of patients had residual cardiac pathology in the form of new onset Atrial Fibrillation. 42% (3/7) of the patients 
required intubation and inotropic support during initial presentation.
Conclusion: Our patients diagnosed with Takotsubo cardiomyopathy follow a similar clinical course and have similar precipitating stressors, 
such as the death of a relative, as reported in other case series. This unusual form of transient cardiomyopathy is more prevalent in middle 
aged females. Full recovery tends to be the norm. However, the acute period of the disease is not benign with up to 42% of patients requiring 
ventilation and or inotropic support. 
Platelet resistance pharmacogenomics and drug interaction: new thoughts for everyday practice
John Benjamin
Morningside Medi-clinic, Sandton, South Africa
The association between CYP2C19 genotype and Clopidogrel treatment outcome has been evaluated so far in two post hoc clinical trial 
analyses (sub studies of CLARITY-TIMI 28 and TRITON-TIMI 38) and fi ve cohort studies. The CYP450 enzyme system is reviewed and 
simplifi ed with relevance to the role of CYP2C19 in converting the prodrug Clopidogrel to its active metabolite. Only 15% of administered 
Clopidogrel is converted to its active form. The CYP2C19*1 allele corresponds to fully functional metabolism, while the CYP2C19*2 
and CYP2C19*3 alleles correspond to reduced metabolism. The *2 variant of the CYP2C19 gene encodes a defective enzyme that fails 
to adequately convert Copidogrel to its active metabolite, leading to lesser inhibition of platelet function and diminished cardiovascular 
protection There appears to be a relationship between the incidence of polymorphisms of CYP2C19 and stent thrombosis. The *2 allele of 
the CYP2C19 occurs in 30% of the population, with minor difference between races. As a result of these observations the US labeling 
for Clopidogrel has recently been updated to include additional information on factors affecting patients’ responses to the drug; this includes 
a large new section on pharmacogenetics and new advice that concomitant use of drugs that inhibit the CYP2C19 enzyme should be 
discouraged. Point-of-care platelet-function tests are available, and some centers are now performing such tests on their PCI patients. 
Fast genotype tests however are not yet available but are in development.The current management of patients at risk is challenging and 
controversial and is being addressed by ongoing trials.



















Histological comparison of the effects of warm ischaemic times on harvested homografts
D. Bester, F.E. Smit, L. Botes and J.J. van den Heever
Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa
Introduction: Homografts in cardiac surgery are well established but availability remains the main limiting factor in their clinical application. 
Homografts are procured from beating heart donors and cadavers with a limited ischaemic time of 12-24 h post mortem. However, this 
time limitation has not been established scientifi cally.  Several publications suggest that it would be acceptable to extend the harvesting times.
Homograft availability is an international problem and the purpose of the study is to extend the harvesting time beyond 24 h, benefi ting 
all cadaver donor based programs.
Methods: The study focused on three groups: (a) Group A (n=5), which contained homograft valves subjected to < 6 h ischaemic time, 
stored at 4C; (b) Group B (n=15), subjected to 24 h, 48 h and 72 h ischaemic times, stored at 4C, after which the valves were processed 
and cryopreserved; (c) Group C (n=15), subjected to 24 h, 48 h and 72 h ischaemic times, stored for 6 h at room temperature (23C), 
followed by 18 h, 42 h and 66 h at 4C, after which the valves were processed and cryopreserved.
Tissue strength was determined by thermal denaturation temperature (Td) and tensile strength.  Tissue morphology was assessed by Scanning 
Electron Microscopy (SEM) and Haematoxylin and Eosin stain.
Results: No statistically signifi cant difference (p>0.05) in tensile strength could be demonstrated between Group A, B and C with no differ-
ences between the three ischaemic time intervals. The results were confi rmed by Td analysis.  Tissue strength did not decrease as a result of 
prolonged ischaemic times or elevated temperatures.
Autolysis were only observed in the 48 h (40%) and 72 h (100%) tissue of Group C but was not suffi cient to affect tissue strength.
The reduction of endothelial cells over time in both Group B and Group C did not infl uence tissue strength up to 72 h.
Conclusion: Based on scientifi c evidence regarding tissue strength it seems acceptable to extend harvesting time to 72 h.
However, animal studies need to be performed to substantiate these results, as the in vivo graft host interactions might produce results that 
are not consistent with these fi ndings.
Predictors of outcome in 176 patients with peripartum cardiomyopathy
Lori A. Blauwet*, Elena Libhaber#, Olaf Forster#, Kemi Tibazarwa#,† and Karen Sliwa#
*Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
# Soweto Cardiovascular Research Unit, Department of Cardiology, Chris Hani Baragwanath Hospital, University of the Witwatersrand, 
Johannesburg, South Africa
†Groote Schuur Hospital, University of Cape Town, South Africa
Background: Peripartum cardiomyopathy (PPCM) is a rare, potentially devastating heart disease that occurs in previously healthy women. 
Factors predicting poor outcome in smaller cases series include left ventricular ejection fraction (LVEF) <30%, left ventricular end diastolic 
dimension > 55mm, and left ventricular thrombus on presentation. The identifi cation of additional prognostic factors for poor outcome 
would be benefi cial in order to provide optimal care for PPCM patients.
Methods: This was a single centre prospective study of 176 women with newly diagnosed PPCM in South Africa. Clinical assessment, 
echocardiography, and laboratory study results including complete blood count, liver function tests, and renal function performed at 
baseline and at 6 months were reviewed. Poor outcome was defi ned as the combined endpoint of death, LVEF <35%, or remaining in 
New York Heart Association functional class III/IV at 6 months. Improved left ventricular systolic function was defi ned as an increase in 
LVEF by a relative increment of >10 absolute units at 6 months.
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Findings: Low systolic blood pressure (p=0.045, OR=0.98) and decreased LVEF (p=0.028, OR=0.95) at baseline were predictors of poor 
outcome. Normal range creatinine (p=0.0367) at baseline predicted improved left ventricular systolic function at 6 months. Neither left 
ventricular dimensions or function, hemoglobin, or liver function tests were predictors of the combined endpoint of poor outcome, 
mortality, or improved left ventricular systolic function.
Conclusion: This large prospective study of patients with newly diagnosed PPCM confi rmed that decreased systolic blood pressure and 
LVEF at baseline predict poor outcome in patients with PPCM, while lower plasma creatinine is a predictor of left ventricular systolic 
improvement at 6 months. No additional prognostic markers could be identifi ed.
Sarcomeric modifi ers of hypertrophy in hypertrophic cardiomyopathy
L.M. Bloem, L. van der Merwe, M. Revera, M. Herandien, A. Goosen, P. Brink and J.C. Moolman-Smook
US/MRC Centre for Molecular and Cellular Biology, Department of Biomedical Sciences, University of Stellenbosch, South Africa
 
Hypertrophic cardiomyopathy (HCM) is an autosomal dominantly inherited cardiac disorder characterised by myocyte disarray, an 
increased risk of sudden cardiac death (SCD) and left ventricular hypertrophy (LVH). HCM thus serves as a model for the investigation of 
LVH, a symptom that is the strongest predictor of cardiac morbidity and mortality after age itself. Interestingly, the extent and pattern of 
LVH in HCM patients shows a large degree of variation even in homogenous patients with the same HCM-causing mutation, indicating 
that additional modifying factors may affect the severity of the cardiac phenotype. 
The development of HCM has been ascribed to mutations in genes that encode primarily constituents of the cardiac muscle contractile unit 
known as the sarcomere. One such gene is TNNT2, which encodes Troponin T, a protein that regulates cardiac contractility in a calcium 
dependent manner via its interaction with tropomyosin. The latter competes with myosin for binding sites upon the actin molecules, and in 
doing so determines binding site availability, the state of which ultimately refl ects the contraction status. Previous studies suggest that compound 
heterozygote individuals for sequence variants in sarcomeric genes are more severely clinically affected compared to simple heterozygous 
disease-causing mutation-carriers. Therefore this study aimed to investigate TNNT2 as a plausible modifi er candidate to potentially identify 
variants in addition to the already documented HCM-causing founder mutations found to be present within our patient group.
The total study population of 227 individuals, belonging to 22 HCM families, carrying one of three known founder HCM-causing mutations 
(R92WTNNT2, R403WMYH7, and A797TMYH7), was genotyped.
Three of the TNNT2 SNPs investigated indicated association with a heritable hypertrophic trait, independent of known hypertrophy 
covariates (p=0.011 indicated association of SNP rs2365652 with maximal interventricular septum thickness (mIVST)). The possibility that 
these fi ndings resulted from linkage disequilibrium between the genotyped SNPs and the R92WTNNT2 founder mutation, was excluded 
by means of Haploview analysis. These data suggest that TNNT2 plays a role as modifi er of the extent of hypertrophy in HCM. This study 
thus contributes to previous hypertrophy research by offering insight into modifi ers of cardiac hypertrophy and highlights the potential for 
future therapeutic intervention studies. 
Hybrid rescue of a severely hypoplastic pulmonary artery
Stephen Brown*, Derize Boshoff# and Marc Gewillig#
*Department of Pediatric Cardiology, University of the Free State, Bloemfontein, South Africa
#Pediatric and Congenital Cardiology, University Hospitals Leuven, Belgium
Management of pulmonary atresia with ventricular septal defect remains diffi cult and challenging. Pulmonary arteries are usually hypoplastic 
and presents diffi culties due to size-mismatch when systemic connection is required. This case report describes the successful novel use of 
a covered stent to facilitate vascular graft connection to a diminutive pulmonary artery during a hybrid procedure.



















Premature fetal closure of the arterial duct: clinical presentations and outcome 
M. Gewillig*, S. Brown#, L. de Catte†, A. de Beer**, B. Eyskens*, V. Cossey**, D. van Schoubroeck**, C. van Hole** and R. de Vlieger†
*Pediatric and Congenital Cardiology, University Hospitals Leuven, Belgium
#Department of Pediatric Cardiology, University of the Free State, Bloemfontein, South Africa
†Prenatal Ultrasound, University Hospitals Leuven, Belgium
**Neonatology, University Hospitals Leuven, Belgium
Introduction: The prevalence of intra-uterine ductal dysfunction is unknown and the clinical consequences are poorly understood. The aim 
of this study was to investigate the echocardiographic abnormalities and outcomes of this rare phenomenon.
Patients and methods: Retrospective analysis of foetal (n=602) and neonatal echocardiographic databases (n=1477) between 1998 and 
2007. Clinical and imaging studies were reviewed for pathology due to or associated with premature closure of the duct. 
Results: Twelve cases were identifi ed. Eight (1.3%) were diagnosed prenatally at a median gestational age of 29.0 weeks (range: 20.037.5 w). 
Four neonates (0.3%) with signifi cant cyanosis and absence of the arterial duct were also included. The most common echocardiographic 
features were: excessive right ventricular hypertrophy (100%), more than expected tricuspid and pulmonary regurgitation (100% and 92%, 
respectively), and right atrial dilation (75%). Premature induction of delivery was advised for 5 patients. Neonatal therapy consisted of 
observation and oxygen administration (n = 7), ventilation with pulmonary vasodilators (n = 5); one required extracorporeal membrane 
oxygenation (ECMO). There were three deaths due to respiratory failure with severe pulmonary hypertension. During follow-up two 
children required additional right heart procedures and one developed a non-compaction cardiomyopathy.
Conclusion: The prevalence of prenatal ductal dysfunction is most likely grossly underestimated. Foetal premature closure of the arterial 
duct causes stress at different foetal ages and many different levels of the right heart and pulmonary circulation, resulting in a wide range 
of secondary pathology. Disproportionate right ventricular hypertrophy is the most common fi nding. Clinical outcomes range from mild 
symptomatology to lethal respiratory insuffi ciency.
Stent expansion of stretch Gore-Tex grafts in children with congenital heart lesions
Stephen Brown*, Derize Boshoff# and Marc Gewillig#
*Department of Pediatric Cardiology, University of the Free State, Bloemfontein, South Africa
#Pediatric and Congenital Cardiology, University Hospitals Leuven, Belgium
Objective: This study evaluated the effi cacy and safety of using stents to enlarge previously placed vascular shunt grafts in children with 
desaturation and congenital heart lesions.
Methods: Bench testing confi rmed the expandability of  3.5 and 4mm vascular grafts  up to 6mm. Eleven patients with desaturation where 
stretch grafts were placed for systemic to pulmonary artery shunts were identifi ed. Stents were selected to be at least 1mm larger in diameter 
then nominal diameter of the implanted graft.
Results:  Fifteen stents were implanted in 11 stretch grafts a median of 18.9 (range: 0.9 62.1) months after shunt surgery. There was a median 
increase in diameter of 136 % (97 228)   from  nominal to fi nal stented diameter of the shunts ( p  = 0.008; 95% CI 0.5 to 2.8). Saturations 
improved from a median of 73% (62 -82) to 87% (79 -89) [p = 0.003; 95% CI 6.5 to 20.1]. No severe complications were experienced 
during the procedures.
Conclusion: In our limited experience, stretch Gore-Tex vascular grafts can be safely expanded beyond nominal diameters using high 
pressure vascular stents. This leads to improvement  pulmonary blood fl ow and saturations. It may potentially allow the clinician to tailor 
pulmonary fl ow to somatic growth. 
256
Temporary use of small stents to delay surgery in children with cardiac disease
D.G. Buys*, S.C. Brown*, F. Smit#, M. Long# and A.D. Bruwer*
*Department of Pediatric Cardiology, University of the Free State, Bloemfontein, South Africa
#Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa
 
Introduction and aim: Critical obstruction of the aorta in small, critically ill neonates and infants is diffi cult to treat. These sick infants 
present signifi cant surgical risk for mortality and the surgical repair itself is challenging. Primary stent implantation is an attractive alternative. 
The aim of this study was to determine the effi cacy, safety and outcome of primary stenting in certain critical obstructive lesions in infants.
Methodology: Retrospective analysis of infants with cardiac disease who needed temporary small stents to delay surgery.
Results: Small stents were implanted in fi ve infants with a median age of 2.0 months (range: 2.2-5.0).  The median weight was 3.9 kg (range 
2.2-5.1), all were severely symptomatic and surgery considered risky. Pre-implantation gradient was reduced from a median of 59.4 mmHg 
pre-implantation to 13.0 mmHg post-implantation (p < 0.001). All coarctation stents were coronary stents and 4F sheaths were inserted in 
the femoral artery. All children could be weaned off ventilation and 3 were subsequently successfully repaired.  In one child the stent was 
replaced with a second larger stent and noteworthy weight gain was achieved. There were no deaths.
Conclusion:  Small stents are effective, safe and results in postponement of surgery. This approach is however, recommended only for very 
sick, small infants where surgical risk is high.  
Genetic variation in Na+/K+-ATPase gene isoforms are associated with extent of left 
ventricular hypertrophy in hypertrophic cardiomyopathy
N. Carstens*, L. van der Merwe#, M. Revera†, M. Heradien**, A. Goosen**, P.A. Brink** and J.C. Moolman-Smook*
*US/MRC Centre for Molecular and Cellular Biology, Department of Biomedical Sciences, University of Stellenbosch, South Africa
#Biostatistics Unit, Medical Research Council of South Africa, Tygerberg, South Africa
†Department of Cardiology, IRCCS San Matteo Hospital, Pavia, Italy
**Department of Medicine, University of Stellenbosch Health Sciences Faculty, Tygerberg, South Africa
Hypertrophic cardiomyopathy (HCM) serves as a model to investigate left ventricular hypertrophy (LVH) development as this primary 
cardiac disease is characterised by LVH in the absence of increased external loading conditions. HCM is mostly caused by mutations in genes 
encoding sarcomeric proteins, but manifests extreme variability in the degree and pattern of LVH, even in HCM patients with the same causal 
mutation, which suggests the involvement of additional genetic modifi ers. Previous studies identifi ed genes encoding renin-angiotensin-
aldosterone system (RAAS) components as modifi ers of the hypertrophic phenotype of HCM. However, most of these investigations were 
centred on a set of so-called pro-LVH polymorphisms in only fi ve genes encoding proteins with roles in the proximal part of the RAAS. 
The Na+/K+-ATPase is one of the downstream effectors of the RAAS and is responsible for maintaining transmembrane gradients of Na+ and 
K+.  The cardiac expression of Na+/K+-ATPase isoforms is altered in heart failure and hypertrophy. This study was therefore aimed at investi-
gating the effect of three single nucleotide polymorphisms (SNPs) within the genes encoding the Na+/K+-ATPase β1, α1 and α2-subunits on 
heritable hypertrophy traits in a HCM cohort of 22 families, each harbouring one of three HCM founder mutations.
One SNP in ATP1B1, rs1200130, was signifi cantly associated with left ventricular mass (LVM) (p = 0.023) and a hypertrophy score derived 
from principal component analysis, PC1, (p = 0.027). Additionally rs7548116 in ATP1A2 was associated with LVM (p = 0.047) and maximal 
left ventricular wall thickness (mLVWT) (p = 0.027), while rs850609 in ATP1A1 was associated with mLVWT (p = 0.038). These associations 
are independent of the primary HCM-causal mutation and other known hypertrophy covariates, such as age, sex and blood pressure. 
This study is the fi rst to implicate Na+/K+-ATPase isoforms in the development of hypertrophy within the context of HCM.  Future studies 
should include downstream RAAS genes, particularly Na+/K+-ATPase isoforms, in hypertrophy modifi er studies. The modest effect sizes 
reported for these variants are similar to those reported for other RAAS variants, which suggests that the hypertrophic phenotype of 
HCM may be the cumulative result of a number of modifi er genes of modest effect. 



















A case of tachycardia-induced cardiomyopathy
Ashley Chin
Cardiac Clinic, Groote Schuur Hospital, Cape Town, South Africa
 
Introduction: Tachycardia-induced cardiomyopathy (TIC) is an important reversible cause of left ventricular (LV) dysfunction that may compli-
cate both supraventricular and ventricular arrhythmias.  Although prior studies have shown that LV function can improve if the tachycardia 
is controlled by medication or ablation, LV function may not normalise and patients may be left with persistent LV dilatation and impaired 
LV function. One small study has also suggested that a recurrence of the arrhythmia may lead to a precipitous decline in LV function.  
Case report: A 56 year old man presented to the cardiac clinic with a 3 month history of dyspnoea and frequent episodic palpitations in 
mild heart failure.  An ECG of an episode revealed a supraventricular tachycardia (SVT) at 200bpm with no baseline pre-excitation in sinus 
rhythm.  An echocardiogram showed a LV ejection fraction (LVEF) of 21%. He was started on metoprolol, enalapril and diuretics.  At a 3 week 
follow-up visit, his symptoms had markedly improved with a repeat echocardiogram showing a LVEF of 51%, confi rming a diagnosis of 
TIC. Unfortunately, he defaulted medical therapy and represented with an identical SVT 4 months later. He underwent an electrophysio-
logical study which confi rmed an orthodromic atrioventricular reentry tachycardia (AVRT) with successful ablation of multiple left lateral 
accessory pathways.  An echocardiogram confi rmed that his LV function had deteriorated to a LVEF of 35%.  At a 2 year follow-up visit, 
he reported no recurrences of palpitations or SVT.  His last follow-up echocardiogram showed a LVEF of 47%.
Discussion: This patient developed a TIC secondary to recurrent episodes of AVRT.  Although medical therapy was successful in controlling 
the episodes of AVRT with a rapid improvement in LV function over a period of 3 weeks, recurrent episodes of AVRT resulted in a precipi-
tous decline in LV function over a period of 3 months.  Successful ablation of the AVRT resulted in improvement but not normalisation of 
LV function.  This case report supports prior observations that LV function may not normalise and that recurrences of the arrhythmia may 
lead to a precipitous decline in LVEF in patients with TIC.  
A 10 year experience of endomyocardial biopsies at Groote Schuur Hospital, Cape Town
Ashley Chin, D. Kapp, H. Wainwright, C. Russouw and A. Okreglicki
Cardiac Clinic, Groote Schuur Hospital, Cape Town, South Africa
 
Introduction: The current role of endomyocardial biopsy (EMB) in the diagnosis and treatment of adult cardiovascular disease remains contro-
versial resulting in wide variations in clinical practice. We report our experience of EMB at Groote Schuur Hospital over a 10 year period.
Methods: We reviewed the indications, histological reports and complications of all EMBs performed at Groote Schuur Hospital between 
1999 and 2009 in non-posttransplanted hearts. All EMBs were performed by either a cardiology registrar or consultant using a fl exible 
bioptone forceps with the aim of obtaining at least 3 samples in more than 1 region from the right ventricular septum via either the right 
internal jugular (predominantly), right subclavian or right femoral vein.
Results: We identifi ed 67 patients who underwent EMB during the study period. The indications were myocarditis in 4, restrictive/infi ltrative 
cardiomyopathy in 17, arrhythmogenic right ventricular cardiomyopathy (ARVC) in 21, and cardiomyopathy of unknown cause (majority 
dilated cardiomyopathy) in 25 patients.  Histology did not support the clinical diagnosis of myocarditis in any of the 4 patients.  A histological 
diagnosis was obtained in 5 patients (3 patients with sarcoidosis, amyloidosis, fi brotic stage of Loeffl ers syndrome respectively and 2 patients 
with ARVC) out of 17 with a diagnosis of restrictive or infi ltrative cardiomyopathy. Histology did not identify a specifi c cause (amyloidosis, 
sarcoidosis or haemochromatosis) in all 25 cardiomyopathy patients. 13 out of 21 with suspected ARVC had histological features compatible 
with the diagnosis.  Insuffi cient sampling occurred in 6 patients. Major complications occurred in 6 patients (3 patients required pericardio-
centesis for cardiac tamponade and 3 patients had suspected RV perforation) with no deaths. 
Conclusion: Our fi ndings strongly support the use of EMB in the diagnosis of ARVC and suspected restrictive/infi ltrative cardiomyopathies.  The 
low diagnostic yield of EMB in myocarditis and dilated cardiomyopathy is compatible with previous studies.  The 9% complication rate supports 
the need for careful risk/benefi t assessment before performing an EMB.
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Radiofrequency ablation of accessory pathways: a 19 year experience of the Cardiac Clinic, 
Groote Schuur Hospital 
Ashley Chin, A. Okreglicki and M. Reid 
Cardiac Clinic, Groote Schuur Hospital, Cape Town, South Africa
Introduction: Radiofrequency ablation (RFA) is fi rst-line therapy in the management of patients with symptomatic accessory pathways (APs). 
There is no published data on the experience of RFA of APs from Africa. 
Methods: The aim of this study was to review the experience of RFA (19902008) at Groote Schuur Hospital in Cape Town and to evaluate 
the accuracy of the Arruda algorithm in predicting the location of APs in 110 patients with the Wolff-Parkinson-White syndrome.     
Results: The study cohort comprised 194 patients with 205 APs who had undergone 230 RFA procedures. There were 98 males and 96 
females, age 33 17 years (range: 1-84), with 25 patients (13%) of black African descent. Symptoms had been present for 8.5 9.9 years (median: 
4.8 years, range: 1 month-60 years) before a RFA was performed. Atrial fi brillation had been documented in 34 patients (18%) before RFA. 
Only 5 patients (3%) had presented with an antidromic tachycardia. 92 APs (45%) were located on the left, 44 APs (21%) in the paraseptal 
space, 40 APs (20%) on the right, and 21 APs (10%) presented with a septal or parahisian location. 8 APs (4%) could not be classifi ed. A 
single AP was found in 184 patients (98%) while multiple APs were noted in 10 patients (2%). 38 patients (20%) had concealed APs.  RFA of 
all pathways were successful in 161 patients (83%). 14 patients (7%) required repeat RFAs. Serious complications occurred in 3 of 230 RFA 
procedures (1.3%). Although the Arruda algorithm had an overall sensitivity of 51% and a specifi city of 97% in predicting the location of an AP, 
it was more useful in correctly localising left-sided (sensitivity 91%, specifi city 96%) and paraseptal APs (sensitivity 82%, specifi city 93%). 
Conclusion: To our knowledge, this is the fi rst reported series of RFA of APs from Africa. The most common APs were left-sided APs, 
followed by postero-septal and right APs. The Arruda algorithm was more useful in identifying left and paraseptal APs than right-sided 
APs. Similar to experience worldwide, RFA of APs at our institution, after an initial learning curve, is highly successful and safe. 
Radiofrequency ablation of a Mahaim accessory pathway in a patient with Ebsteins anomaly
Ashley Chin and A. Okreglicki
Cardiac Clinic, Groote Schuur Hospital, Cape Town, South Africa 
Introduction: Mahaim accessory pathways are associated with Ebsteins anomaly.  Antidromic atrioventricular reentry tachycardia (AVRT) over 
a Mahaim pathway is typically a left bundle branch block (LBBB) morphology tachycardia. We report an unusual case of Ebsteins anomaly 
with a right-sided Mahaim pathway associated with an antidromic AVRT without a typical LBBB morphology.
Results: A 20 year old man with Ebsteins anomaly presented with a 1 year history of episodic palpitations. A resting 12-lead ECG revealed 
sinus rhythm with no pre-excitation, atypical right bundle branch block (RBBB), and a QRS axis of +45 degrees.  An ECG of one of the 
palpitations revealed a wide complex tachycardia at 192bpm, QRS duration 170ms, QRS axis 60 degrees, with a RBBB-like morphology in 
leads V1-V3 with different QRS morphologies compared to the resting 12-lead ECG.  At electrophysiological study, a similar antidromic 
AVRT was easily induced with atrial and ventricular programmed electrical stimulation. Antegrade conduction over a decrementing 
accessory pathway (Mahaim pathway) was confi rmed.  Endocardial mapping localised this pathway to the posterior-septal (5 o’clock) tricuspid 
annulus which was successfully ablated.    
Conclusion: Most studies have reported Mahaim pathways with antidromic AVRT to have a LBBB confi guration with an rS pattern in lead 
V1 with a precordial QRS transition ≥ V5. We describe a patient with Ebsteins anomaly and a confi rmed right-sided Mahaim pathway with 
an antidromic AVRT with a RBBB-like pattern in leads V1-3. We suggest that this patient has a long atrioventricular pathway because of 
no baseline pre-excitation, a QRS axis of -60 degrees and wide QRS complex antidromic tachycardia (170ms).  The pathway probably 
inserts into the posterior wall of the right ventricle accounting for the positive concordant QRS morphologies in the right-sided chest 
leads (V1-V3).  An alternative explanation is that the dilated right atrium and atrialised right ventricle has displaced the heart relative to the 
surface ECG electrodes with loss of the typical early activation and LBBB pattern in the right-sided chest leads.  We hypothesize that 
Ebsteins anomaly with a right-sided posterior-septal Mahaim pathway may not display the typical LBBB pattern during antidromic AVRT as 
seen in structural normal hearts.        



















Is dosage adjustment of low molecular weight heparin necessary and safe for pregnancies 
at greatest risk of thrombosis?
R.S. Chitsike, P. Manga, H.A. Rhemtula and B.F. Jacobson
Departments of Haematology, Cardiology and Obstetrics and Gynaecology, Johannesburg Hospital, University of the Witwatersrand and 
NHLS. South Africa
 
Introduction: Pregnancies at greatest risk of thrombosis include patients with mechanical prosthetic heart valves in the mitral position and 
patients with atrial fi brillation. Guidelines of the 7th American College of Chest Physician conference recommend the use of Low 
Molecular Weight Heparin (LMWH) as an option to attain adequate maternal thromboprophylaxis in these patients.
Aim: To determine whether dosage adjustment of LMWH in order to maintain an Anti-Xa of 1.0-1.2 IU/L is both necessary and safe for 
pregnancies at the highest risk of thrombosis. 
Methods: This was a prospective study consisting of 6 pregnant patients with either mechanical prosthetic heart valves (n=5) or atrial 
fi brillation (n=1). Patients were started on LMWH at a dose of 1mg/kg twice daily and the dose adjusted to achieve an Anti-Xa of 
1.0-1.2 IU/L. The LMWH dose was adjusted weekly or fortnightly throughout pregnancy and a monthly echocardiogram was performed 
to exclude the presence of valvular or atrial thrombosis. 
Results: Marked inter-patient and intra-patient variation was noted in the dose required to maintain a therapeutic Anti-Xa as the 
pregnancy progressed, with one patient achieving over double the initial dose required. None of the patients developed bleeding or 
valvular/atrial thrombosis.
Conclusion: LMWH thromboprophylaxis with dosage adjustment appears both necessary and safe during pregnancy. However, a larger 
sample size would be required to test this hypothesis fully.
Echocardiographical features of two infants with anomalous coronary arteries
A.M. Cilliers, P. Adams and G. Dumani
Department of Pediatric Cardiology, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa
Introduction: The echocardiographic diagnosis of anomalous coronary arteries requires a high index of suspicion in all cases of global 
myocardial dysfunction in children. The value of transthoracic echocardiography in making the diagnosis is highlighted.
Case reports: We present two infants,  4 months and 9 months of age who presented with dilated cardiomyopathy and heart failure. 
Echocardiography in both infants showed poor left ventricular function, hyperechoic changes of the endocardium and the papillary muscles 
suggestive of endocardial fi broelastosis, mitral incompetence, and abundant septal intramyocardial coronary fl ow signals. In each case an 
abnormal coronary was seen arising from the main pulmonary arterial trunk. The 4 month old child was found to have a typical anomalous 
left coronary artery from the main pulmonary artery (ALCAPA). The 9 month old child displayed the rare form of anomalous origin of 
the coronary artery where the right coronary artery was noted to be arising from the main pulmonary artery (ARCAPA). The diagnosis 
was confi rmed angiographically and the patient underwent successful surgical reimplantation of the right coronary artery into the aorta.
Discussion: ALCAPA and even more so, ARCAPA, are very rare congenital abnormalities (0.0023 live births). They represent the most 
common causes of myocardial ischaemia and infarction in children and if left untreated results in a mortality rate of 90% within the fi rst year 
of life. The clinical course and prognosis depends on the extent of collateralisation between the RCA and the LCA. Anomalous origin of the 
coronary arteries may be associated with other cardiac defects e.g. ventricular septal defect, coarctation of the aorta and tetralogy of 
Fallot. Echocardiography typically establishes the diagnosis by demonstrating the origin of the coronary artery from the pulmonary artery 
and characteristic Doppler fl ow patterns.
Conclusion:  Echocardiography is a useful modality to screen for anomalous coronary artery disease. The combination of a dilated cardio-
myopathy in the presence of endocardial fi broelastosis, mitral incompetence and should alert one to the possibility of abnormal coronary 
origins in infants.  Colour fl ow Doppler abnormalities within the vessels and the myocardium may assist with the diagnosis. Angiography can 
be used to confi rm the diagnosis. 
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Assessing rheumatic mitral stenosis with the proximal isovelocity surface area (PISA) 
method: validation of the PISA method against the invasive gold standard (Gorlin 
formula)
F.M. Claassen, A.L. Mbonambi, P.G. Herbst and A.F. Doubell
Division of Cardiology, Department of Medicine, University of Stellenbosch and Tygerberg Hospital, South Africa
 
We have recently proposed the use of the proximal isovelocity surface area (PISA) technique to determine mitral valve area (MVA) in 
patients with mitral stenosis to overcome the weaknesses of the standard echocardiographic technique, 2-D planimetry (Herbst et al. 
SA Heart, 2008, 5; 224).  The aim of this study was to validate the PISA method against the invasive gold standard, the Gorlin formula.
Methods: Patients diagnosed with mitral stenosis undergoing percutaneous mitral balloon valvuloplasty (PMBV) during an 18 month period 
were included.  Transthoracic echocardiography was used to calculate MVA using the PISA method and 2-D planimetry.  Hemodynamic data 
was captured during the PMBV procedure.  The Gorlin formula was used to calculate valve area from the hemodynamic data.
Results: Eight patients were studied in this pilot phase. MVAs calculated using echocardiography varied between 0,4 cm 1,6 cm. Three 
patients had mild aortic incompetence and all 8 patients had mild mitral incompetence.  One patient had mildly impaired systolic function 
(EF=58%).  MVAs calculated using the Gorlin formula varied between 0,4 cm 1,4 cm.  PISA correlated well with both the echocardiographic 
gold standard and the invasive gold standard including the patients with associated valve dysfunction.
Conclusion: The PISA method is a robust method to determine MVA in patients with mitral stenosis that ranges from mild to moderate. 
The PISA method correlates well with both the echocardiographic and the invasive gold standard for determining valve area.
Phytosterol-enriched foods: evidence for their cholesterol-lowering effi cacy and combi-
nation with other lipid-lowering approaches
Isabelle Demonty
Unilever R&D Vlaardingen, The Netherlands
The cholesterol-lowering properties of phytosterols (PS) are known since the 1950s. In the 1980s, the esterifi cation of PS with fatty acids 
from vegetable oils eased their incorporation into fat-based foods. A meta-analysis of trials with fat-based foods enriched with PS esters 
showed a non-linear relationship between the daily dose of PS consumed and cholesterol-lowering effi cacy. On average, 2.0-2.4 g/day PS 
lowered LDL-cholesterol (LDL-C) concentrations by 8.9%, with little additional benefi t at intakes higher than 2.5 g/day (Katan et al., 2003). 
Several dietary recommendations include the daily consumption of 2 g of PS as a dietary option to lower elevated LDL-C concentrations. 
More recently, additional evidence became available for the cholesterol-lowering effi cacy of PS incorporated in a wide variety of food 
formats, including low-fat or fat-free foods such as milk and yogurt, and single daily dose food formats such as yogurt drinks. Two recent 
meta-analyses including studies with these new food formats investigated the impact of food format on PS effi cacy. AbuMweis et al. (2008) 
calculated an average effect for subgroups of PS doses. In our meta-analysis (Demonty et al. 2009) we established a continuous dose-
response equation allowing predicting the LDL-C lowering effect of a given dose of PS in populations. We observed no signifi cant dif-
ferences between dose-response curves established for plant sterols vs. stanols, fat-based vs. non fat-based foods and dairy vs. non-dairy 
foods. Both single and multiple daily intakes of PS signifi cantly lowered LDL-C, but there was a tendency towards a slightly lower effi cacy 
of single vs. multiple daily intakes. PS-enriched foods are effi cacious in subjects consuming a typical Western diet as well as a heart healthy 
diet and in subjects taking cholesterol-lowering medications such as statins or fi brates. The combination of PS with fi sh oil for a dual benefi t 
on both LDL-C and triglycerides, either as fi sh oil fatty acid esters of PS or as a combination of PS-enriched foods and fi sh oil capsules has 
an overall benefi cial effect on blood lipid profi le. However, results on the nature of possible interactions between fi sh oil and PS on LDL-C 
and triglycerides are inconsistent, warranting further investigations. 



















Mitral stenosis in pregnancy
A.F. Doubell, U. Lalla, H. Weich and P. Herbst
Division of Cardiology, Department of Medicine, University of Stellenbosch and Tygerberg Hospital, South Africa
The hemodynamic changes induced by pregnancy are poorly tolerated by patients with mitral stenosis (MS), often precipitating the onset 
of symptoms and the need for intervention. Percutaneous balloon mitral valvotomy (PBMV) is an effective intervention if the anatomy is 
suitable, but valve replacement (MVR) during pregnancy may be required in very diseased valves. Limited data is available for PBMV and MVR 
during pregnancy in the South Africa population.  We review the management and outcome of MS in pregnancy at our institution to deter-
mine if the South African experience mirrors the experience recorded in other populations. 
We review our experience with MS in pregnancy with emphasis on 31 patients who underwent PBMV and 10 patients who underwent 
valve replacement during pregnancy over a ten year period, comparing the outcomes with intervention in non-pregnant patients. 
Patients undergoing interventions for MS are often diagnosed before pregnancy (55% of patients undergoing PBMV) indicating that opportu-
nities are missed to address the valve lesion prior to conception. Conversely, patients in whom MS is identifi ed for the fi rst time in preg-
nancy (45% of patients undergoing PBMV) often present late in the second trimester. Beta blockers are the mainstay of medical treatment 
for MS but obstetricians are often reluctant to use beta blockers in pregnancy. A low threshold is required for PBMV during pregnancy in 
patients with severe MS and suitable valves as procedural success is high (97%) with signifi cant improvement in mitral valve area (1.05 ±0.20 cm 
to 1.73 ±0.35 cm [p<0.001]) and reduction in mean transmitral gradient (14.4 ±8.3mmHg to 6.6 ±3.4mmHg [p<0.001]) in the pregnant 
group, mirroring the results in non-pregnant patients. Complications included mitral regurgitation (17%), anaphylaxis (3%), atrial fi brillation 
(6%) and TIAs (6%). The latter emphasises the hypercoagulable state of pregnancy. Favourable outcomes were maintained at follow-up 
(mean 2.78 ±2.71 years). No maternal deaths occurred in our patients undergoing PBMV or MVR during pregnancy. Perinatal loss was 25% 
for women undergoing MVR but fetal loss following PBMV was limited to a single patient in whom the procedure was performed as an 
emergency on a ventilator.
Inter-sectoral and regional healthcare cooperation in southern Africa: The Namibian 
childrens heart project 
H. du Toit*, S. Vosloo# and C. Hugo-Hamman†
*Panorama Medi-Clinic, Cape Town, South Africa
#Christiaan Barnard Memorial Hospital, Cape Town, South Africa
†Christiaan Barnard Memorial Hospital and Constantiaberg Medi-Clinic, Cape Town, South Africa
Introduction: Both public private sector and regional cooperation have been proposed as useful tools to alleviate critical shortages in 
health service provision in southern Africa.  The aim of this project is the development of cardiac services for Namibian children and it was 
initiated at the request of the Ministry of Health of Namibia.  
Methods: This is a review of a cohort of 60 patients with congenital or rheumatic heart disease referred for heart surgery over the period 
April 2007 to August 2009 (28 months).  The majority of patients were recruited from the Paediatric Heart Clinic at Windhoek Central 
Hospital.  
Results: Sixty (60) patients with age 7 days to 29 years received a total of 73 operations.  Only 2 had surgery for rheumatic heart disease 
and there were 3 adults with congenital heart disease.  There have been no deaths. There were 11 re-operations in 8 patients.  Four (4) patients 
needed surgery for post-operative complications. Twenty-six (26) patients were on private health insurance. Of the 33 indigent state 
patients, 8 were paid for by a charitable trust and 25 by the Namibian Government.  Eight operations were performed in state hospitals 
and the balance (65) in private hospitals in Cape Town.  
Conclusions: With goodwill, political commitment and cooperation, this project provides strong evidence for supporting expansion of 
public private partnerships in the health sector in southern Africa.  
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Assessment of warfarin control in patients with operated valvular heart disease in one 
hospital in Sudan 
 
Ahmed ElSayed and Hanin Osama Mohammad
AlShaab Teaching Hospital, Khartoum, Sudan
Introduction: Warfarin is one of the commonest causes of death related to prescription drugs. It’s pharmacology is complicated and many 
factors need to be considered in the optimal management of each patient. In this study our aim is to study the control of warfarin in patients 
with operated valvular heart disease and to identify the factors that make it diffi cult to control and suggest improvements.
Objectives: To assess warfarin control in patients with operated valvular heart disease and to classify them as controlled or not. To determine 
the incidence of INR control complications. To try to determine factors that may infl uence poor control.
Methods: This is a retrospective hospital based study in valve replacement patients done by one surgeon in one hospital. After the patients 
were contacted and consented the data was collected by a questionnaire from the hospital computer database and further by reviewing the 
patient’s fi les and interviewing them. It was then analysed using SPSS.
Results: 70 patients (40 males) were enrolled. Age range is 15-75. The majority are from the west but 75% live in Khartoum or nearby. MVR 
was the commonest operation (38 patients with AVR 17 and DVR 15). Mean warfarin dose was 5.3 (range 113). Of all 70 patients only 10 
patients had good INR  control. 68.6% of patients test INR at irregular intervals. The 31.4% who follow up regularly do it at different intervals 
{4.3% twice a month, 14.3% monthly, 4.3% 2 monthly, 5.7% 3 monthly and 2.9% 6 monthly}.
The most common complication was bleeding which happened to 45.7% during the course of their treatment, it was however mainly minor 
bleeding (which will be further explained). Only one patient developed severe retroperitoneal bleeding required hospitalisation. The other 
noted complaints were nausea in 8 and priapism in 2 patients.
Conclusions: Warfarin control as it now stands in Sudan Heart Center is very unsatisfactory. Reasons for this and possible solutions will be 
presented. The proposed solutions are the subject of ongoing studies now.
More then 10 years of open heart surgery in Sudan: a presentation and suggestions for 
the future 
Ahmed ElSayed and Alamin Alawad
AlShaab Teaching Hospital, Khartoum, Sudan
Introduction: Open heart surgery has come a long way globally since its foundations were fi rst laid in the 1950s. Today about 1 million cases 
are done annually globally with a global average of 167 open heart cases/million of population. In Africa however, only 29 open heart cases/
million population are done annually giving a total of 25 000 cases per year in the whole of Africa. So it is obvious that Africa is very much 
behind the global average. This situation is more bleak when one realises that the European average is 3 times and the North American 
average is 5 times the global average. Sudan is doing relatively better than most of Africa but we are faced with a really uphill struggle to 
reach the global average. In this paper we present the open heart cases done in Sudan since it restarted in 1998 and present the case 
for expansion in this specialty in a developing world setting.
Objectives: To review all the cases done in Sudan since it restarted in 1998 till December 2008.
Methods: This is a retrospective and prospective hospital based study in the period from 01/01/1998 to 31/12/2008. The data was from 
the hospital computer database and further by reviewing the patient’s fi les.  The data was analysed using SPS package.
Results: Nearly 5 000 patients had open heart surgery in the period of the study. These varied between rheumatic heart disease patients, 
ischaemic surgery patients, congenital heart disease patients and other patients.  The trends in the numbers and variety of these cases over 
the years is detailed in the presentation.
Conclusions: Sudan has in a short while reached a good standard in the numbers of open heart procedures being done  and there are a 
large number of cases of different variety being done. Complications (including mortality) are high but reasonable when patient profi le is 
considered. This is only the beginning for the country as a whole and the need for more centres and more international cooperation is 
evident. This could also serve as a regional nucleus for the surrounding countries.



















Development of a hand-held device for automated paediatric cardiac auscultation
P.R. Fourie*, J. Lawrenson#, R. de Decker†, A. van Niekerk**, Joan Hunter¥, M.L. Cronje*, O.M. Strydom* and E. Pretorius* 
*Diacoustic Medical Devices, Stellenbosch, South Africa
#Red Cross Children’s Hospital and Stellenbosch University, South Africa
†Red Cross Children’s Hospital, Cape Town, South Africa
**Mowbray Maternity Hospital, Cape Town, South Africa
¥Louis Leipoldt Medi-Clinic Hospital, Bellville, South Africa
 
Background: Most of the heart murmurs detected in children are innocent. The skills of the fi rst examiner are in most cases not adequate 
to distinguish between innocent and pathological murmurs, resulting in a large percentage of unnecessary referrals. The aim of this project 
was to develop a hand-held medical electronic device that could record heart sounds digitally, analyse the recording and aid the examiner 
in distinguishing between innocent and pathological murmurs.
Methods: Heart sound recordings of more than 400 patients were obtained, recorded at four positions on the chest, resulting in more 
than 1 600 recordings. The dataset contains recordings of 222 pathological and 45 functional murmurs, as well as recordings of 133 normal 
hearts without any murmurs. All pathological and functional murmurs were correlated to the presence or absence of cardiac abnormalities by 
echocardiogram. These recordings were used to develop the decision support algorithm.  A touch screen hand-held device was developed 
using a three lead ECG and electronic stethoscope as input.
Results: Heart sound recordings of the most common innocent and pathological murmurs are presented as examples of the recorded 
data. The device functions well and the heart sound analysis methods are discussed with the possible advantages to the medical examiner. 
A screening sensitivity and specifi city of respectively 90% and 96.5% were achieved in the initial tests conducted.
Conclusions: The accuracy by which medical examiners could distinguish between innocent and pathological murmurs could be improved 
by using a simple hand-held device. The device will be able to save, display,  analyse and transmit the heart sound recording as well as the 
patient information. It is anticipated that this would reduce unnecessary referrals and improve the quality of referrals to cardiologists, while 
also reducing the fi nancial and emotional impact that further referrals have on parents and their children.  
Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis: 
roles of sphingosine-1-phosphate, ERK1/2 and Stat3
Miguel Frias, Ursula Lang, Christine Gerber-Wicht and Richard W. James
Hatter Cardiovascular Research Institute, Faculty of Health Sciences, University of Cape Town, South Africa
Aims: We analysed the impact of native and reconstituted (artifi cial) high density lipoproteins (HDL) on doxorubicin induced cardiomyocyte 
apoptosis. Whilst an effective anti-cancer agent, doxorubicin has serious, cardiotoxic side effects. Conversely, HDL has been shown to 
protect cardiomyocytes notably against oxidative stress.
Methods: Cultured neonatal rat ventricular cardiomyocytes were subjected to doxorubicin-induced stress, monitored as caspase3 activation 
and apoptotic DNA fragmentation. The protective effects of HDL and sphingosine-1-phosphate were investigated using native HDL 
isolated from human serum, reconstituted HDL of varied composition and agonists and antagonists of sphingosine-1-phosphate (S1P) 
receptors. Anti-apoptotic signaling pathways were identifi ed with specifi c inhibitors.
Results: Native and reconstituted HDL signifi cantly decreased doxorubicin-induced cardiomyocyte apoptosis. It was essentially attributable 
to the sphingosine-1-phosphate component of HDL. The effect of the latter was mediated by the S1P2 receptor, but not the S1P1 or 
S1P3 receptors. The ERK1/2 signaling pathway was required for the anti-apoptotic effects of HDL and sphingosine-1-phosphate. The tran-
scription factor, Stat3, also played an important role as inhibition of its activity compromised the protective effects of native HDL and 
sphingosine-1-phosphate on doxorubicin-induced apoptosis.
Conclusions: HDL and its sphingosine-1-phosphate component can protect cardiomyocytes against doxorubicin toxicity and may offer one 
means of reducing cardiotoxic side effects during doxorubicin therapy. The study identifi ed anti-apoptotic pathways that could be exploited 
to improve cardiomyocyte survival.
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A novel model of Endothelial Dysfunction (ED) in cultured Cardiac Microvascular Endo-
thelial Cells (CMECs)
Amanda Genis, Eva Madau, Amanda Lochner and Hans Strijdom
Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, South Africa
Introduction & objectives: ED occurs when the endothelium, in the presence of exposure to harmful circulating stimuli, associated with 
cardiovascular risk factors, produces reduced amounts of nitric oxide (NO), a potent vasoldilator.  ED is now recognised as the earliest, 
independent predictor of atherosclerosis and therefore has promising therapeutic value in prevention of ischaemic heart disease.  Most studies 
focus on macrovascular ECs and the aim of this study was to establish a model for ED in CMECs and investigate possible cellular mecha-
nisms.  To achieve this, several cardiovascular risk factors were simulated in vitro to induce ED, which was defi ned as reduced intracellular 
NO-production.
Experimental approach: Rat CMEC cultures (4th 10th generations) were incubated with:
1. Glucose (25mM for 24h;  30mM for 72h)
2. Angiotensin II (Ang II) (100nM for 24h)
3. TNF-α (5ng/ml for 24h)
The following investigations were performed:
1. Cell viability:  propidium iodide fl uorescence.
2. NO production:  DAF-2/DA fl uorescence.
3. Total and activated eNOS expression in TNF-α groups (Western blot analysis)
4. Total and activated PKB expression in TNF-α groups (Western blot analysis)
Results: (1) 25mM glucose had no signifi cant effect on NO levels. (2) 30mM glucose increased NO levels signifi cantly. (3) Ang II had no 
effect on NO-production. (4)  In TNF-α groups, a modest, but signifi cant reduction in NO production was found in all three parameters 
assessed (91.133.22%, 94.252.58% and 93.421.95% respectively vs. 100% for control, p < 0.05). Furthermore, a reduction in activated 
eNOS (0.600.27 vs. 1 for control) and a signifi cant reduction in activated PKB (0.310.13 vs. 1 for control, p < 0.05), were observed in 
TNF-α treated groups.  None of these interventions had signifi cant effects on cell viability.  
Discussion & conclusion:  An in vitro model of ED has for the fi rst time been described in CMECs using TNF-α as the ED-inducing factor. 
It appears as if the model is associated with increased inactivation of PKB and eNOS, which could help explain the reduced NO-produc-
tion observed.  This can lead to possible further exploration of the mechanisms and signaling involved in ED in CMECs. 
Infective endocarditis in a HIV positive population
R. Goncalves, J. Vorster, R. Garda, G. Angel, L. Mkhwanazi, N. Lester, N. Ruhamya and P. Manga 
Department of Cardiology, CM Johannesburg Academic Hospital, University of Witwatersrand, Johannesburg, South Africa
 
Aims: The association between HIV and infective endocarditis remains poorly defi ned. The aim of this study was to compare HIV positive 
to HIV negative patients with infective endocarditis admitted to CM Johannesburg Academic Hospital in terms of patient demographics 
and outcomes.  
Methods: The study was a prospective observational study over a 3.5 year period.  The modifi ed Duke criteria were used to classify patients 
as having a defi nite, possible or rejected case of IE. 
Results: 56 patients were identifi ed as defi nite or possible IE. Of these 17 (30%) were HIV positive; defi nite (11) and possible (6). The 
remaining 39 patients were HIV negative. In the HIV positive cohort a female preponderance (1.4:1) was noted with a mean age of 35.3 
years (range 22 - 67 years) as compared to a male preponderance (1.78:1) in the HIV negative patients with a mean age of 43.2 years 



















(range 16 - 76 years). Nine (53%) HIV positive patients had chronic rheumatic heart disease, based on standard clinical and echocardio-
graphic criteria, compared to 25 (64%) in the HIV negative group. Five (29%) HIV positive patients and four (10%) HIV negative patients 
were intravenous drug abusers. No HIV positive patient had degenerative heart disease but fi ve HIV negative patients had degenerative 
valvular disease (aortic stenosis and myxomatous mitral degeneration). 
A positive blood culture was confi rmed in 41% of patients among HIV positive patients versus 51% in HIV negative patients.
The mortality rate was 29% (5 deaths) and the same percentage underwent valve replacement in the HIV positive group. In the HIV negative 
group the mortality rate was 38.5% (15 deaths) and 46% (18 patients) underwent valve replacement.  
Conclusion: As compared to HIV negative patients with IE, HIV positive patients with IE tend to be younger and female. Similar pre-
disposing factors are present in both groups. Our study suggests that HIV is not a risk factor for infective endocarditis per se. Contrary 
to popular belief the prognosis is not worse in the HIV positive group as compared to the HIV negative group. Thus both groups should 
be treated similarly, medically and surgically.
Infective endocarditis at CM Johannesburg Hospital: a prospective review
R. Goncalves, J. Vorster, R. Garda, L. Mkhwanazi, G. Angel, N. Lester, N. Ruhamya and P. Manga 
Department of Cardiology, CM Johannesburg Academic Hospital, University of Witwatersrand, Johannesburg, South Africa
 
Aims: The epidemiology of infective endocarditis (IE) throughout the world continues to evolve. The aim of this study was to evaluate the 
demographics and patient outcomes of patients admitted to CM Johannesburg hospital with a presumed diagnosis of infective endocarditis.  
Methods: The study was a prospective observational study. Patients referred with probable IE were prospectively enrolled over a three and 
a half year period.  The study collected only in-hospital data during the index admission. The modifi ed Duke criteria were used to classify 
patients as having a defi nite, possible or rejected case of IE.
Results: A total of 65 patients were identifi ed with a presumptive diagnosis of IE.  31 (48%) had a defi nite diagnosis of IE. In 25 patients 
(38%) the diagnosis was possible and in 9 it was rejected. Of the 56 patients with a defi nite or possible diagnosis of IE a male predomi-
nance (1.3:1) was found with a mean age of 40.8 years (range 16-76 years). Thirty four patients (61%) had chronic rheumatic heart 
disease, based on clinical and echocardiographic fi ndings. Five patients had degenerative valvular disease (aortic stenosis and myxomatous 
mitral degeneration). Nine patients had a history of intravenous drug abuse, 1 had a prosthetic cardiac valve and 2 had intravascular haemo-
dialysis catheters. The aetiological agent was confi rmed on blood culture in 27 patients (48%), with Streptococcus Viridans and Staphylo-
coccus Aureus being the most common isolates. Cultures were negative in 52% of patients. Heart failure was very common (82%) as was 
renal failure (43%). 30% of the patients were found to be HIV positive. 41% of patients required valve replacement. The overall in-hospital 
mortality for this cohort of patients was 35%.
Conclusion: Patients with infective endocarditis tend to be young. The most common predisposing risk factor is chronic rheumatic 
valvular disease followed by degenerative valve disease. A high culture negative rate was noted possibly due to prior treatment with anti-
biotics or collection of insuffi cient samples. The prevalence of HIV in this study was high, probably a refl ection of the burden of this disease 
in the community. The in-hospital mortality for IE remains very high. 
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Percutaneous closure of a subclavian artery to Innominate vein fi stula in a neonate
K. Govendrageloo and J. Harrisberg
Sunninghill Clinic, Sandton, South Africa
Introduction: Congenital Arteriovenous fi stulae are fairly uncommon. Congestive cardiac failure may be a presenting feature dependent on 
the size of the communication from the high pressure arterial bed to the low-pressure venous circuit. 
Case report: Dilated right heart chambers were detected antenatally by ultrasound. Term female neonate born by C/S weighing 3.24kg. 
No immediate problems. Prominent continuous murmur and radiological cardiomegaly noted immediately after birth. Normal vital signs. 
ECG: SR. 146/min. Axis: +240. RA +. RV +.
CXR: Increased CTR - 73%. Clear lung fi elds.
ECHO: Normal venous return to RA and LA. PFO with L->R fl ow. Dilated RA, RV, MPA. Mild TI with mild + PHT. Very dilated Innominate 
vein and RSVC. Abnormal fl ow from LSA to Innominate vein via a short fi stulous connection .
CTA: Small PDA. Short fi stula from LSA -> Innominate vein. Mild Isthmal hypoplasia.
INTERVENTIONAL PROCEDURE: Successful percutaneous occlusion of the fi stula with a 6:4 Type 1 Amplatzer PDA occluder.
Conclusion: An uncommon  congenital arteriovenous fi stula was found in a neonate -> right heart  volume overload and the potential for 
CCF.  Following  preliminary investigations, successful percutaneous occlusion of the fi stula was undertaken. 
Hybrid procedures to the aortic arch
D.G. Harris, A. Saaiman, D. du Toit and G. Rossouw
Kuilsriver Hospital, Kuilsriver, South Africa
Objective: Traditional repair of aortic arch aneurysms requires cardiopulmonary bypass and a period of  profound hypothermia and circulatory 
arrest - allowing  detachment of the head vessels off the aneurysm, and their anastomosis onto the graft. The procedure is safe and reproducible, 
however complications include air embolism, stroke, excessive bleeding, and acidosis. In addition the procedures are time consuming, and 
cardioplegic arrest is also necessary, resulting in the potential for low cardiac output.
With improving techniques of descending aortic repair with stent grafts, hybrid techniques (which involve aortic arch debranching followed 
by stenting over the aortic arch) are becoming popular.
Methods: Four cases are presented. The technique involves initial sternotomy or upper sternal split, detachment of the innominate and left 
common carotid arteries, and their re-attachment (transposition) to the ascending aorta by separate grafts (debranching procedure). The left 
subclavian is usually left intact for technical reasons – this is safe as the shoulder has adequate collateral circulation, and therefore stenting 
over this vessel is well tolerated. The aortic arch is then completely covered with a stent graft which is inserted via the femoral artery.
Results: Case 1: Repair of traumatic aortic dissection involving the arch.
A 33 year old male patient involved in an MVA sustained traumatic dissection of the descending aorta with retrograde extension into the arch. 
Repair would require clamping over the carotid artery and its re-attachment onto the graft with or without circulatory arrest – a technically 
diffi cult and risky procedure. Upper sternal split was performed, and a side clamp placed on the ascending aorta while a bifurcated graft was 
sewn in place. The innominate and left carotid arteries were transected and grafted to the graft. The left subclavian artery was left intact. 
After closure the patient was immediately transferred to the cath lab where the aortic arch was successfully stented. Follow up angiogram 
shows no endoleak. At 4 year follow up he remains well, with no claudication in the left arm. CT has been repeated and shows good 
position of the prosthesis.
Case 2: Off pump repair of saccular arch aneurysm.
This 65 year old male presents with a saccular aneurysm of the aortic arch, involving the innominate and left carotid arteries. Sternotomy 
was performed, a side clamp placed on ascending aorta, and a bifurcated graft attached. The innominate and left carotid arteries were 



















sequentially transected and attached to the graft. Stenting had originally been planned, but the aneurysm was amenable to surgical closure: 
a long clamp was placed across the arch, below the aneurysm, and it was excised and oversewn.
Case 3: Repair of left subclavian aneurysm with dissection into the descending aorta. 
This 75 year old male patient presents with chest pain. Cardiac catheterisation confi rms triple vessel disease, as well as a saccular aneurysm 
of the left subclavian artery. This has caused a dissection which extends into the descending aorta. CABG was performed, with vein grafts to 
LAD, circumfl ex and right coronary, and at the same time the left carotid and subclavian arteries were detached and grafted to a bifurcated 
graft from the ascending aorta. One month later a stent graft was placed over the arch from the innominate artery and over the aneurysm.
Case 4: Staged replacement of entire thoracic aorta.
A 58 year old female patient presents for repair of ascending aortic aneurysm. This measures 55mm, the arch 35mm, and descending aorta 
42mm. The aneurysm extends up to and involves the innominate artery. Cardiac cath shows proximal LAD disease. Stage 1 involved vein 
graft to LAD, transection of the innominate artery, graft replacement of ascending aorta up to level of left carotid, and attachment of 
innominate lower down on graft via a 10 mm graft. Stage 2 was performed when the patient (lost to follow up) presented after 5 years 
with symptomatic 7cm aneurysm of distal descending aorta. Two 45mm x 15cm stent grafts were inserted from proximal aorta to the level 
of the coeliac artery.  Stage 3 is available if arch replacement is indicated in future (presently measures 40mm). This would involve a stent 
across the arch after  performing carotid-carotid grafting from right carotid. 
Conclusions: Endovascular repair of the descending thoracic aorta, initially reserved for inoperable patients, is now becoming the accepted 
initial management.  With improved technology and grafts it is now the safest option, especially for traumatic dissection. With debranching 
techniques available, stenting over the aortic arch, as a hybrid procedure is yielding gratifying results. Good pre-operative planning is 
necessary to make the procedure feasible.
Repeat coronary artery bypass grafting: the role of the off pump left thoracotomy 
approach
D.G. Harris and J.A. Saaiman
Kuilsriver Hospital, Kuilsriver, South Africa
Objective: Repeat CABG has increased risks, including injury to patent grafts. We have evaluated the thoracotomy procedure, using the 
off pump technique in all patients.  The procedure is well documented but reported data is limited to case reports and small series.
Methods: There were 55 patients over an 8 year period. Mean age was 63.2 years (41-82), and age at previous operation was 51.7 years 
(31-69). Predicted mortality was 14.1% (logistic EuroSCORE).
Results: Forty three patients had intact LIMA grafts. The LIMA was used in 7 patients, where it had not been used before. Stenting, as a 
hybrid procedure was performed in 13 patients (23.6%) during the same admission.  There were 91 distal grafts (including 4 sequentials). 
We performed 54 venous, and 26 radial artery grafts. 21 patients had 1 distal graft, 32 had 2 distals, and 2 had 3 distals performed (average 
1.6 grafts per patient). It was possible to graft the distal right coronary branches (PDA or RPL) in 10 patients. Mean blood loss (24 hours) 
was 380mls, mean ventilation time 4.8 hrs (0-12), icu stay 2.7 days(2-8), and hospital stay 6.3 days (5-20). There was one postoperative 
death (1.8% mortality). 
Conclusion: The procedure is safe, especially with patent LIMA-LAD grafts, and risks are decreased. Multislice CT scanning allows 
better preoperative planning, especially regarding sites of proximal graft implantation, allowing a less invasive incision. The procedure is 
now considered to be the method of choice for patients requiring redo surgery for lateral wall grafting especially when there is an intact 
LIMA to LAD graft.
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Pre-operative data
Number of patients 55 %
Mean age 63 41-82
Age at previous op 51.7 31-69
Congestive failure 7 2.7
Diabetes 25 45.5
EF 30-50% 21 38.2
EF<30% 4 7.3
Pre-op IABP 9 16.4
Pre-op inotropes 5 9.0
Previous stents 15 27.3
Peripheral vascular disease 11 20.0
Carotid disease 4 7.3
Calcifi ed aorta 9 16.4
Unstable angina 25 45.5
2nd redo 4 7.3
Vessels stented (as hybrid procedure)
Right coronary artery                    6
LAD                                            3
Circumfl ex                                   1
Large septal perforator                  2
Mainstem                                    1
Total                                       13
Post-operative data
24 hour blood loss     380 (mls) 125-1100
Ventilation time 4.8 (hrs) 0-12
ICU stay 2.7 (days) 2-8
Hospital stay 6.5 days 5-20
Early death 1 patient 1.8%
Late death (1 year postop) 1 patient 1.8%
Re-angiogram (all grafts intact) 4 patients 7.3%
Percutaneous management of a complex coarcataion, PDA and mycotic aortic aneurysm: 
case report
J.R. Harrisberg and K. Govendrageloo
Sunninghill Clinic, Sandton, South Africa
Introduction: Complex coarctation with added pathology such as acquired mycotic aneurysms in the region of the coarctation may present 
as diffi cult and challenging surgical cases.  These patients may often be better managed percutaneously with a variety of new stents which 
have recently become available.
Case Study: A 27year old male with Down Syndrome was born with an Atrio-Ventricular Septal Defect (AVSD), left ventricular outfl ow 
tract obstruction and a mild coarctation of the aorta.  At the age of 4 months he underwent a successful surgical repair of the AVSD.  At the 
age of 7 years he had a resection of a progressing subaortic membrane. He was then followed up for many years and was relatively asympto-
matic. He developed Staph Aureus infective carditis at the age of 18 years which was succesfully managed with antibiotics. This was 
followed by a diagnosis of spinal osteitis at the age of  26 years which again was treated with a prolonged course of antibiotics. 
Over the more recent years, he had developed a severe long tunnel subaortic stenosis as well as a progressive severe coarctation of his 
native aorta associated with upper limb hypertension. At the age of 27 years, a CT angiogram to demonstrate the anatomy of the coarcta-
tion of the aorta, revealed a surprise fi nding of a large mycotic false aneurysm beneath the coarctation of the aorta and a long small PDA. 
He was turned down for surgery and percutaneous stenting of the coarctation and the aneurysm was attempted.
Procedure: In the cath lab, the patient underwent a successful percutaneous closure of the PDA with an Amplatzer Duct II device, 
complete relief of the coarctation of the aorta with a covered CP stent and then isolation of the mycotic aneurysm with a Relay stent graft. 
He now awaits surgery of his left ventricular outfl ow tract.
Conclusion: Complex coarctations of the aorta with added pathology such as mycotic aneuryms may be readily managed in the cath lab 



















10 year single centre experience with percutaneous ASD occlusion and surgical closure 
J.R. Harrisberg, K. Govendrageloo, R. Kinsley, P. Colsen, H. Mamorare and G. Martin
Sunninghill Clinic, Sandton, South Africa
Introduction: Amplatzer ASD occluders were introduced to South Africa in October 1999. Since then the number of percutaneous 
closures of secundum ASD’s has steadily risen. At the same time, the surgical cases have not diminished much.
Method: This study is a non-randomised, retrospective observational analysis looking at both the percutaneous closure group and the 
surgical repairs over a 10 year period in a single centre.
Percutaneous group: 153 patients were taken to the cath lab with intention to close the secundum defects. 19 were rejected based on 
unsuitable anatomy with transoesophageal echocardiography (TEE) and were subsequently sent for surgery. 132 patients had 135 devices 
successfully implanted. There were 2 failures (wire entangled in chiari network and one case of temporary heart block). Both were sent 
for surgery. 
Surgical group: Together with the 21 cases referred from the percutaneous group, a total of 143 cases were closed surgically over the 10 
year period.
Follow up: Immediate and short term complications in both groups will be discussed in detail. In addition, the medium to long term follow 
up will be presented.
Conclusions: Percutaneous closure of selected secundum ASD’s is a very effective and successful alternative with distinct advantages 
over surgical repair. Follow up has shown these cases to be free from medium to long term complications.
PCI in diabetics: real world data: a comparision to the CARDia trial 
Peter Haworth, Sue Ellery, Miles Behan, Mrinal Saha, Anna Stubbs, Stephen Holmberg, David Hildick-Smith and 
Adam de Belder
Cardiology Research Unit, Sussex Cardiac Centre, Brighton, UK
Introduction: 1 year mortality in diabetic patients with multivessel disease randomised to PCI in the CARDia trial showed no statistical 
difference to those randomised to CABG. Slow recruitment and failure to meet target numbers may have lead to selection bias. To 
assess whether the CARDia PCI is relevant to day-to-day practice, we analysed diabetic patients treated with PCI in our centre to assess 1 
year mortality. 
Methods: Baseline details were recorded peri-procedurally. 1 year follow up was performed by questionnaire. Mortality data was collected 
by analysis of the NHS strategic tracking system. Patients older than 80, with left main stem disease and patients with cardiogenic shock 
were excluded. 
Results: 1 217 patients who met the CARDia admission criteria were included for analysis. There was no difference in age (65 years vs 64 
years p=ns), gender (male 71% in each group p=0.5) or pre intervention EF < 50% (43% vs 45% p=0.7). In our group there was a lower 
incidence of DES use (23% vs 71% p=<0.001), glycoprotein IIBIIIA inhibitor use (4.3% vs 95% p+<0.001) and hypertension (62% vs 76% 
p=<0.001) along with a much higher incidence of acute patients (50% vs 22% p= <0.001) and a history of smoking (46% vs 37% p=0.01). 
Insulin use was higher in the CARDia patients but not statistically signifi cant (25% vs 31% p=0.06). Mortality at 1 year was 3.2% in the 
CARDia group vs 4.8% in our group (p=0.37). 
Conclusion: Despite a higher incidence of PCI for acute coronary syndromes in our group, 1 year mortality is statistically no different than 
that of CARDia. We argue that our group more closely represents real world practice in PCI in diabetics. These results are a signifi cant 
improvement on 1 year outcome seen in the BARI trial and support the use of PCI in diabetic patients.
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Syncope and sustained ventricular tachycardia predict mortality in Arrhythmogenic Right 
Ventricular Cardiomyopathy: evidence from the ARVC registry of South Africa
 
Neil Hendricks, David A. Watkins, Z. Brian Vezi, Francesca Little, Motasim Badri, Andrzej Okreglicki and 
Bongani M. Mayosi
The Cardiac Clinic, Groote Schuur Hospital, Observatory, Cape Town, South Africa
Background:  Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a progressive heart muscle disorder that manifests with ventricular 
arrhythmias, heart failure and sudden death. Little is known about the outcome of patients with ARVC in South Africa.
Methods: Subjects were recruited to the ARVC Registry of South Africa from 2004 to 2009. Fifty unrelated cases were confi rmed to have 
ARVC according to published criteria. Details on presenting symptoms, family history and annual follow-up were collected. Kaplan-
Meier survival analysis was performed, and cohort survival was compared to the general South African population using the Chi-square 
test. Coxs proportional hazards regression models were fi tted to identify risk factors associated with mortality.
Results: All major South African racial groups and both genders were represented in the cohort, though there was a preponderance of 
Caucasians (80%) and males (66%). Presenting characteristics were similar to cohorts in Europe and North America. Nine individuals (18%) 
died over a median follow-up of 4.55 [129-8.89] years. The mean age at death was 36.9 14.7 years, annual mortality rate was 2.82%, and 
fi ve-year cumulative mortality rate was 10%. Overall survival was similar to the general South African population (p=0.99). Implantable 
cardioverter-defi brillators (ICDs) were placed in 20 subjects (40%). No subjects with an ICD died over the follow-up period, compared 
with 9/30 (30%) deaths in those without an ICD (Chi-square test p=0.007). In univariate analysis, history of syncope and sustained ventri-
cular tachycardia were the only two parameters associated with death (p=0.017 and p=0.020, respectively); these remained signifi cant 
in multivariate analysis (HR 10.73, 95% CI 1.88-61.18, p=0.008 and HR=22.97, 95%CI 2.33-226.18, p=0.007, respectively). 
Conclusions: The mean age of death (36.9  14.7 years) of South Africans with ARVC is lower than elsewhere (54 19 years). Survival is 
however comparable to the overall South African population, which is experiencing an increase in mortality due to the colliding epidemics 
of HIV/AIDS and non-communicable diseases. Presentation with syncope or sustained ventricular tachycardia are poor prognostic factors 
and mandate consideration for ICD implantation.
Lucky to be alive: complex mediastinal AV fi stula and false aneurysm case report
K.M. Hossain, R.F. Chauke, P.S. Ramoroko and S.M. Mazibuko
Department of Cardiothoracic Surgery, University of Limpopo, South Africa
Penetrating injury of the thoracic aorta is uncommon but mostly fatal, and more so are mediastinal arteriovenous(A-V) fi stulae.  Very few 
patients survive long enough to need surgical treatment and a minority of them develop chronic aorto-venous fi stula. Chronic post traumatic 
aortovenous fi stula patients present with features of congestive cardiac failure and need a specialised imaging procedures for precise anatomical 
diagnosis and well planned surgical intervention sometimes with cardiopulmonary bypass and hypothermic circulatory arrest. We report a 
case of a 19 year old patient with chronic aortic arch-left brachiocephalic vein fi stula and aneurysm.  The patient presented about 2 years after 
a stab to the left parasternal area with neck swelling, distended left sided neck and chest veins and in heart failure.  Investigations undertaken 
were: Chest x-ray, echocardiogram, arch angiogram and thoracic CT angiogram. Chest x-ray revealed widened mediastinum and cardio-
megally. Arch angiogram showed ill-sited mediastinal arteriovenous fi stula and aneurysm with rapid venous runoff. CT-angio improved localisa-
tion of the fi stula and also revealed multiple aneurysms.  Intra-operative fi ndings were through and through injuries of distal brachocephalic 
vein, the aortic arch at the origin of the bovine trunk and under surface of the arch with multiple aneurysms.  Successful repair of the pathology 
was done using cardiopulmonary bypass, hypothermic circulatory arrest and selective antegrade cerebral perfusion. Patient was discharged 
home without major neurological defi cit but had developed delayed post-pericardiotomy pericardial effusion which resolved with drainage. 
Successful repair of chronic mediastinal A-V fi stula with minimal neurological complications can be achieved with multidisciplinary cooperation 
and a well planned surgical approach.



















Pre-treatment with a DPP-4 inhibitor is cardioprotective insulin resistant rats
B. Huisamen, A. Genis and A. Lochner
Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, South Africa
Therapy based on the incretin hormone, glucacon-like peptide-1 (GLP-1) is currently hailed as one of the most promising treatments for 
type 2 diabetes, also because GLP-1 is cardioprotective in animals as well as humans. Because GLP-1 is rapidly degraded by depeptidyl-
peptidase IV (DPP4), some research has focused on inhibitors of this enzyme to raise levels of GLP-1, the latter being attenuated in type 2 
diabetes. We have tested whether pre-treatment of obese, insulin resistant rats, known to present with cardiovascular pathology, with a 
DPP4 inhibitor, is cardioprotective.
Obesity was induced by hyperphagia in Wistar rats (DIO) for a period of 12 weeks whereafter control fed and DIO animals were treated 
with 10mg/kg/day of the DPP4 inhibitor PFK275-055 (Novartis) given orally set in a gelatine/jelly cube.  After 4 weeks of treatment, animals 
were sacrifi ced in a non-fasting state, trunk blood collected for biochemistry, body weight and intra peritoneal (IP) fat weight recorded, 
pancreases harvested for histology and the isolated hearts perfused (Langendorff with regional ischaemia to determine infarct develop-
ment).  Ventricular myocytes were prepared via standard collagenase perfusion techniques to determine insulin stimulated glucose uptake.  
Results: GLP-1 levels were attenuated in DIO and restored by treatment while glucagon levels were 56.7% lower in DIO animals coupled 
to 49% higher insulin levels. These were not affected by treatment. No effects were found on weight, IP fat or blood glucose levels.  DIO 
animals presented with 43.44.6% infarct of area at risk vs control = 30.73.7 and DIO treated = 30.113.1; P<0.05, n=6.  Coronary fl ow was 
enhanced from 16.80.7 to 200.6 ml/min, p=0.008, n=6 in control hearts but no effect found in DIO hearts. No sensitisation of cardio-
myocytes towards insulin could be detected in cells from DIO animals while controls cells presented with a higher fold increase in glucose 
uptake after treatment. No effects on beta-cell neogenesis were found.  
Conclusions: Pretreatment with the DPP4 inhibitor PFK275-055 is cardioprotective in obese animals but did not alleviate insulin resistance 
over a 4 week treatment period.
2-D echocardiographic evaluation of neonates with respiratory distress
Rakesh Jalota and S.S. Sarkar
Vivekanad Polyclinic and Institute of Medical Sciences, Lucknow, India and Sarkar Medical Diagnostic Centre Pvt Ltd, India
Purpose: To evaluate signifi cance of 2-D echocardiography in neonates with respiratory distress in 1st week of life due to congenital cardiac 
defects(CCD).
Method: Total 240 neonates with respiratory distress were echocardiographied in detail were reassessed six weeks later and data was analysed.
Results: Total infants: 240 (135 males, 105 females), Normal 82 (34.16%), with CCD 158 (65.85%), FTND-118, FTCS-97, PMND-18, 
PMCS-7. It was found that the most common defect among the neonates having CCD was Patent Ductus Arteriosus (43%), Atrial Septal 
Defect (11.39%), Patent foramena ovale (10.75%), PDA+ASD/PFO (11.35%) and 25.9% were associated with mild to signifi cant 
Pulmonary Arterial Hypertension, PAH ranged from 32.11mmHg to 64.17mmHg (Avg 43.22mmHg) Total percentile of CCD among the
type of birth viz. FTND, FTCS, PMND & PMCS were almost the same. After six weeks, reassessment by 2D echo it was found that all 
PDA, ASD, PFO & VSD were closed except two large ASD and one subcostal VSD, PAH was reversed to normal in all neonates and they 
were also clinically stable.
Conclusion: In neonates with respiratory distress apart from primary lung problem another major contributory factor is the congenital 
cardiac defects with PAH (25.94%) which probably due to the left to right shunt from congenital cardiac defects. Within six weeks majority of 
the neonates improved, CCD closed and PAH was also normalised.
It is therefore concluded that all the neonates with respiratory distress, if found to have CCD with left to right shunt and PAH should be 
deferred from active intervention and should be managed medically up to 6 to 8 weeks as there is signifi cant chance of their improvement 
due to spontaneous closure of left to right shunt and resolution of PAH.
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Percutaneous pericardioscopy in tuberculous pericarditis: improving the diagnostic yield
C.G. Kyriakakis, H. Weich and A.F. Doubell
Division of Cardiology, Department of Medicine, University of Stellenbosch and Tygerberg Hospital, South Africa
Introduction: Tuberculous pericarditis remains an important cause of morbidity and mortality in the developing world with an increasing 
prevalence due to the HIV pandemic. Defi nitive diagnosis via direct identifi cation of the mycobacterium bacillus is challenging and not 
always possible via conventional investigations. Previous studies have demonstrated a low yield of acid fast bacilli or Mycobacterium tuber-
culosis culture on pericardial fl uid alone. 
Objective: To evaluate the potential advantage of percutaneous pericardioscopic biopsy of the pericardium in tuberculous pericarditis.  
Methods: All patients presenting to the Division of Cardiology, Stellenbosch University and Tygerberg hospital, with a large non-traumatic 
pericardial effusion (epicardial separation distance > 10mm) were offered participation. Each patient underwent pericardiocentesis via a 
standard procedure followed by percutaneous pericardioscopy and pericardial biopsy via a fl exible fi bre optic pericardioscope. Pericardial 
fl uid evaluation included: biochemistry including adenosine deaminase level, cell count, acid fast bacilli (AFB) and tuberculosis (TB) culture. 
Pericardial biopsy specimens were evaluated for AFBs, TB culture and histologically for granulomas.
Results: Sixteen patients agreed to participate. Pericardial biopsy could be obtained in 11 patients, all of which were uncomplicated. Mean 
age was 35. Six (54,5%) had associated HIV disease and 2 (18,2%) presented in clinical tamponade. Six (54,5%) had macroscopic 
evidence of pericardial infl ammation with an exudative surface visualised at pericardioscopy. Seven patients (63,6%) were found to have 
defi nite pericardial TB. Three of the remaining 4 had an alternative diagnosis. Six of the 7 patients with proven TB were AFB positive 
on pericardial biopsy. In none of these patients could AFBs be seen on fl uid and only fi ve fl uid samples subsequently cultured TB within 
42 days (mean time 23,2 days). 
Conclusion: In contrast to the assessment of pericardial fl uid where a defi nite diagnosis of TB is dependant on culture, biopsy enabled a 
more rapid diagnosis via demonstration of acid fast bacilli.  
Innate immunity and protection against reperfusion injury via the SAFE pathway
Lydia Lacerda, Sarin Somers, Lionel Opie and Sandrine Lecour
Hatter Cardiovascular Research Institute, Faculty of Health Sciences, University of Cape Town, South Africa
Introduction: Although the cytokine, tumour necrosis factor alpha (TNFα), is considered to have mainly detrimental effects, brief perfusion of 
TNFα, at the onset of reperfusion, confers protection against lethal reperfusion injuries. We hypothesised that TNFα confers protection via 
the activation of STAT-3, a pathway recently described as the survivor activating factor enhancement (SAFE) pathway.
Methods: Hearts from wildtype (WT), TNF-/-, or cardiac specifi c STAT-3 defi cient (STAT-3 -/-) mice were isolated, mounted on a Langendorff 
perfusion system and subjected to 35 min global ischaemia (I) followed by 45 min of reperfusion (R) (CTL). Ischaemic postconditioning 
(IPostC) was performed by 6 alternative cycles of 10 sec reperfusion, 10 sec ischaemia. In a separate group, pharmacological post-
conditioning with TNFα was performed by 6 cycles of alternative perfusion with/without 0.5ng/ml TNF for 10 sec (TNF-PostC). AG 490, 
a STAT-3 inhibitor, wortmannin, an Akt inhibitor, or PD98059, an inhibitor of Erk1/2, were given during the fi rst 15 min of reperfusion with 
either postconditioning protocol. Infarct size (IS) was evaluated at the end of the protocol. In a separate set of experiments, hearts were 
collected after 15 min of reperfusion for Western blot analysis.
Results: Both IPostC and TNF-PostC reduced infarct size in WT hearts compared to their CTL group (182% and 181%, respectively, p<0.05 
vs 483% for their respective CTL,) but failed to protect the TNF-/- and STAT-3-/- mice.  Similarly, the infarct sparing effect of TNF-PostC 
was abolished in the presence of AG-490 but remained unchanged in the presence of wortmannin or PD98059. Phosphorylated levels of 



















STAT-3, were increased after TNF-PostC stimulus in the nucleus from 182 arbitary units (AU) for I/R, p<0.05 to 546 AU. Similarly Erk1/2 
phosphorylation was increased from 91AU for I/R to 262AU while Akt phosphorylation was decreased after the TNF stimulus from 182AU 
for I/R p<0.05 to 61AU.
Conclusion: Ischaemic postconditioning protects against reperfusion injury via the activation of the SAFE pathway which involves the 
activation of the innate immune system and the transcription factor, STAT-3. Our data provide a novel therapeutic target to limit the 
lethal effects of reperfusion injury.    
Melatonin found in red wine: just a sleep away from cardioprotection
Kim Lamont, Lionel Opie and Sandrine Lecour
Hatter Cardiovascular Research Institute, Faculty of Health Sciences, University of Cape Town, South Africa
Introduction: Moderate chronic consumption of red wine (2-3 glasses/day) can protect against cardiovascular disease. However, the exact 
components found in the wine, which can account for this protective effect, still need to be delineated. Recently, the presence of melatonin, 
a hormone that regulates circadian rhythms, has been detected in red wine. Interestingly, melatonin also protects against experimental 
ischaemia reperfusion injury. Therefore, we hypothesized that the presence of melatonin in red wine contributes to the cardioprotective 
effect of chronic red wine consumption. In addition, we propose that the protective effect of melatonin occurs via the activation of the 
transcription factor signal transducer and activator of transcription 3 (STAT3), known to protect against ischaemia reperfusion injury.
Methods: The drinking water of male Wistar rats was supplemented with red wine (equivalent of 2 glasses per day) or melatonin (0.075g/
day).  After 10 days of treatment, hearts were perfused on the Langendorff system and subjected to 30min global ischaemia (I) followed 
by 60min of reperfusion (R). Functional parameters were recorded throughout the experiments and infarct size was measured at the end 
of the protocol. Rate pressure product (RPP) measured at 60min of reperfusion was expressed as a percentage of baseline value.
Results: Control hearts subjected to I/R presented a rate RPP of (16.4% 2.7). A chronic treatment of red wine or melatonin improved RPP 
to a similar level (28.5% 2.7 and 27.4% 2.9, respectively, p<0.001 vs control). Interestingly, pretreatment with red wine or melatonin were asso-
ciated with an increase in STAT3 phosphorylation compared with the control groups (70% for red wine and 79% for melatonin). Further-
more, experiments conducted in the presence of AG490, a STAT3 inhibitor abolished the protective effect of melatonin or red wine. 
Conclusion: Our data strongly suggest that melatonin may account for the protective effect of chronic moderate consumption of red wine 
and that this protective effect is mediated via the activation of STAT3 activation. 
Cardiac abnormalities in thoracopagus conjoined twins. The Red Cross Children’s 
Hospital experience
 John Lawrenson, John Hewitson, Jenny Thomas, Richard Pitcher and Alastair Millar
Department of Paediatrics and Child Health, University of Stellenbosch and School of Adolescent and Child Health, University of Cape Town, 
Red Cross Children’s Hospital, Cape Town, South Africa
During the past 4 decades, the surgical unit at the Red Cross Children’s hospital has become an expert centre in the evaluation and 
treatment of conjoined twins. In thoracopagus twins, the extent of cardiac sharing may determine whether separation is possible. In this 
brief review, the evaluation of cardiac abnormalities in the 24 sets of thoracopagus twins will be discussed. The author will  highlight the 
technical diffi culties and ethical dilemmas which characterise the management of these patients. 
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HIV cardiomyopathy is associated with a low body mass index: evidence from a case-
comparison study
C.E. Lemmer, M. Badri, M. Visser and B.M Mayosi
Department of Medicine, Groote Schuur Hospital, Cape Town, South Africa
Introduction: The cause of cardiomyopathy in patients infected with human immunodefi ciency virus (HIV) remains largely unknown, although 
a number of predisposing factors have been identifi ed. Malnutrition has been postulated as a contributory factor but the association 
of malnutrition with HIV-associated cardiomyopathy  has not been established in prospective studies.
Method: We prospectively investigated the association between nutritional state measured by anthropometric measures of lean body mass 
and HIV positive individuals with and without cardiomyopathy.
Results: 17 cases of HIV-associated cardiomyopathy (HIVAC) and a comparison group of 18 HIV positive patients without heart disease 
were recruited. There were no signifi cant differences in age, CD4 cell count, HIV RNA viral load and WHO clinical stage of HIV 
disease between the two groups.  HIVAC cases had evidence of malnutrition compared to those without cardiomyopathy:  a signifi cantly 
lower Body Mass Index (cases: 20.9kg/m2; controls: 27.0kg/m2; P=0.02), Mid-Upper Arm Circumference (cases: 26.2cm; controls: 27.3cm; 
P=0.02), and Bone Free Arm Muscle Area (cases: 26.7cm2; controls: 32.8cm2; P=0.02). However, in a multi-variate step-wise logistic 
regression model, body mass index (BMI) was the only independent anthropometric risk factor for cardiomyopathy (odds ratio = 0.73 95%CI 
0.64-0.97, p=0.02).
Conclusion: Cardiomyopathy is associated with a lower BMI in people who are living with HIV. 
Mechanism of melatonin-induced cardioprotection: let me count the ways...
Amanda Lochner
Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, South Africa
Melatonin (N-acetyl-5-methoxytryptamine) is synthesized mainly by the pineal gland and regulates mammalian and circadian rhythms. It is a 
highly conserved molecule found in organisms from unicells to vertebrates. Melatonin is a potent free radical scavenger and an anti-oxidant 
and is highly effective against oxidative stress.  For example, melatonin is 5 and 14 times more effective at scavenging the highly toxic hydroxyl 
radical than is either glutathione and mannitol respectively. Melatonin is involved in many physiological systems including the cardiovascular 
system. Melatonin effectively protects the heart against ischaemia-reperfusion damage, having both acute and long-term effects. Although 
these effects were initially attributed to its free radical scavenging abilities and anti-oxidant activity, recent evidence suggested a role for the 
melatonin receptor, since its benefi cial effects are abolished by luzindole, a melatonin receptor blocker. In addition, melatonin has potent 
anti-adrenergic actions, involving nitric oxide, guanylyl cyclase and PKC, which have been shown to participate in melatonin-induced cardio-
protection. Simultaneous administration of melatonin and inhibitors of nitric oxide synthase or guanylyl cyclase abolished cardioprotection.
Recent studies showed that melatonin also protected the mitochondrial integrity and functional capacity by virtue of its free radical scavenging 
actions and it was suggested that it may directly interact with the mitochondrial permeability transition pore, keeping it in a closed 
confi rmation.
There is continued interest in discovering new cardioprotective agents of high potency and low toxicity. Melatonin fulfi lls most of these criteria 
and the virtual absence of toxicity renders it a good candidate for long-term use. However, all studies thus far have been done on animals and 
only one clinical trial is currently in progress where melatonin is used as an adjunct in patients with acute myocardial infarction undergoing 
angioplasty. Clearly the outcome of such a study may play a pivotal role in the decision to use melatonin in patients with ischaemic heart disease 
or to use the drug prophylactically.



















Cell death in ischaemic injury: a dynamic response concept
Ben Loos and Anna-Mart Engelbrecht
Department of Physiological Sciences, University of Stellenbosch, South Africa
Autophagy, apoptosis and necrosis have previously been described as distinct static processes that induce and execute cell death. Due to 
an increased use of novel techniques in mapping cellular death the existence of grey zones between cell death modes have been 
revealed. Therefore, we aim to dissect out the molecular overlap between the cell death modes and to place them into clear context of 
autophagic activity, the intracellular metabolic environment and kinetics of the cell death modes. It is hypothesized, that cell death is a dynamic 
response scheme with autophagy as a central role player in providing cellular adaptability and ensuring highest likelihood for cell survival. 
A model of simulated ischaemia (SI) is employed using the cardiac myoblast cell line H9c-2. Cells were submitted to a protocol of 2, 4 and 
8 hours of SI followed by 1 hour reperfusion. To modulate SI severity, 2-deoxy-glucose, sodium dithionate and a combination thereof 
are employed. We evaluated the contribution of the cell death modes using viability- and ATP assays. LC3, Beclin-1, Cyt-c and HMGB-1 
were evaluated using 3-dimensional fl uorescence and live cell-imaging techniques, Western blot analysis and fl ow cytometry.
Our results indicate a differential induction of cell death, which is dependent on the duration, severity of SI and the metabolic state of the 
cell. The inhibition of glycolysis leads to the induction of autophagy, to signifi cantly increased ATP generation and pyknosis. The inhibition 
of mitochondrial respiration fails to induce an autophagic response but rather induces loss of membrane integrity. An onset delay of 
apoptosis and necrosis is suggested, when the autophagic machinery is induced in time. These fi ndings indicate the urgent need to address 
the cell’s metabolic capacity in context with cell death parameters from a dynamic perspective. 
Recognition of cardiac abnormalities with the aid of a precordial auscultation device
W.W.Lubbe*, J.S.F.Botha#, H.S.Weich†, P.G.Herbst†, I.B.Louw†, H.L.Koekemoer**, C.Scheffer# and A.F.Doubell†
*Division of Internal Medicine, University of Stellenbosch and Tygeberg Hospital, South Africa
#Department of Mechanical and Megatronic Engineering, University of Stellenbosch, South Africa
†Division of Cardiology, Department of Medicine, University of Stellenbosch and Tygerberg Hospital, South Africa
**Geoaxon Holdings (Pty) Ltd., South Africa
Introduction: A precordial auscultation device (PAD) has been developed with the aim of screening for cardiac disease by differentiating 
between normal and abnormal heart sounds and recording an ECG. The use of the PAD as a screening tool to assess the auscultation data 
of a patient might prove useful for healthcare workers in rural communities by improving the detection of cardiac abnormalities and 
preventing inappropriate referrals. Our aim was to determine the sensitivity and specifi city of the PAD to detect cardiac disease.
Methods: Sixty people were recruited of which 30 had normal hearts and 30 had abnormal hearts, as determined by echocardiography. 
All participants were examined by a cardiologist and had PAD auscultatory and ECG recordings performed. The cardiologist and PAD 
fi ndings were separately used to classify participants as normal or abnormal. This was then compared to the echocardiographic diagnosis 
and sensitivities and specifi cities calculated. An ECG using the PAD was recorded which was categorised by the cardiologist as normal, 
abnormal or quality insuffi cient to comment. 
Results: Seven of the 60 PAD recordings could not be analysed due to technical diffi culties (data not included in this analysis). The PAD 
correctly identifi ed 16 of the 28 abnormal participants (sensitivity 57%) and 21 of the 25 normal participants (specifi city 84%) with a 
positive predictive value of 80% and a negative predictive value of 63%.The ability to detect abnormality was enhanced by using the PAD ECG 
together with the PAD recordings, resulting in a sensitivity of 86% and a specifi city of 71%. The positive and negative predictive values 
were 75% and 83% respectively. The PAD accuracy was unaffected by weight, height, BMI or chest circumference.
Conclusions: The PAD when used together with the information supplied by the PAD ECG is a sensitive and specifi c tool to screen for 
cardiac disease. 
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Comparison of PCI and CABG in shortening the QTc interval, and correlation with the 
incidence of sudden cardiac death
K. Majola, M. Heradien, A. Goosen, P. van der Bijl, P. Brink and A. Doubell
Department of Medicine, Faculty of Health Sciences, University of Stellenbosch and Tygerberg Hospital, South Africa
Objectives: To compare the effect on shortening of the QTc interval obtained via Percutaneous Coronary Intervention (PCI) or Coronary 
Artery Bypass Grafting (CABG) and by extrapolation, the incidence of sudden cardiac death after abovementioned procedures.
Methods: All patients admitted to Tygerberg Academic Hospital (TAH) for angiography, and subsequently progressing to a revascularisation 
procedure (either PCI or CABG, according to standard indications) during 2009, were included. Bazetts formula was employed to manually 
calculate QTc-intervals prior to and immediately after revascularisation, as well as one day prior to or upon hospital discharge. The mean, 
nett, difference in QTc-intervals (prior to and immediately after revascularisation) between the two groups (PCI vs. CABG) were compared.
Results: In the PCI group, 41 patients have been entered thus far, 32 males (78% of the population). The mean, pre-PCI QTc was 435 ms, 
and the mean, post-PCI QTc was 412 ms. This translates to a mean, nett difference of 23 ms. In the CABG group, 20 patients have been 
entered thus far, 16 males (80% of the population). The mean, pre-CABG QTc was 444 ms, and the mean, post-CABG QTc was 404 ms. 
This translates to a mean, nett difference of 40 ms. CABG appears to shorten QTc more than PCI. 
Conclusions: It has been proven that both procedures improve coronary perfusion and cardiac systolic function, but CABG has a more 
dramatic effect on mortality. In this preliminary study, CABG also appears to shorten the QTc more than PCI, which would suggest that 
the difference in QTc is a potential, surrogate marker for mortality in this context. If a clear correlation can be proven between QTc 
shortening and sudden cardiac death, even more credibility will be added to using QTc as an index for mortality in the setting of ischaemic 
heart disease and revascularisation procedures.
Life threatening chronic traumatic broncho-pulmonary arterial fi stula 
M.R. Manganyi, R.F. Chauke and P.S. Ramoroko 
Department of Cardiothoracic Surgery, Medunsa Campus, University of Limpopo, South Africa
Bronchovascular fi stula occurs rarely following pulmonary resection occurring in 3% of patients who have undergone bronchoplastic pro-
cedure. Other cases of bronchopulmonary fi stula were reported after tracheobronchial stents, lung transplantation and CABG. Its occur-
rence is even rarer following gunshot wounds to the chest. Literature search for penetrating traumatic bronchovascular fi stula are very hard 
to come by. No article could be found that addresses bronchial – pulmonary arterial fi stula following penetrating injuries to the chest. We 
report an unusually presentation of major haemoptysis in a 37 year old male patient presenting 17 years after gunshot to the chest with 
bullet in-situ. The patient was transferred to our institution after presenting at the local hospital with massive haemoptysis. Investigation 
undertaken included chest X-ray and CT scan of the chest which revealed right upper lobe consolidation with foreign body in the peri-
hilar region. The patient was taken to theatre for emergency right upper lobectomy. During dissection the fi stula was discovered between 
the pulmonary artery and the right upper lobe, where the patient was bleeding into the pulmonary parenchyma, hence the haemoptysis. 
The lobectomy and the fi stula were successfully repaired and the bullet retrieved. The patient was well at sixth months follow-up. High 
index of suspicion is therefore needed for management and good outcome.



















Mutations in plakophilin 2 gene are a common cause of Arrhythmogenic Right Ventricular 
Cardiomyopathy in South Africa: evidence from the ARVC Registry of South Africa
M. Mbele, G. Shaboodien, M. Parker, N. Hendricks, D. Watkins, A. Okreglicki, H. Moolman-Smook and B.M. Mayosi
Hatter Cardiovascular Research Institute, Faculty of Health Sciences, University of Cape Town, South Africa
Background: Genetic mutations in the plakophilin-2 (PKP2) gene cause 10-43% (average 26%) of cases of inherited arrhythmogenic right 
ventricular cardiomyopathy (ARVC) in Europe and North America. The prevalence of PKP2 mutations in South African patients with ARVC 
is not known. The aim of the study was to determine the prevalence of PKP2 mutations in patients with ARVC in South Africa.
Method: Thirty-six DNA samples from unrelated probands with ARVC were screened for variants in 14 exons of PKP2 using denaturing 
high-performance liquid chromatography and sequencing. Population frequencies of novel PKP2 variants were determined in control individuals 
by SNaPshot and restriction enzyme digestion. As a rare novel variant recurred in three apparently unrelated ARVC probands, deter-
mination of common ancestral haplotype was done by means of microsatellite marker genotyping across a 300kb region on chromosome 
12 (NC_ 000012.10) in which PKP2 resides. 
Results: Seven PKP2 gene mutations, 5 of which were novel, were found in 8/36 (22%) unrelated participants. The novel C1162T mutation 
occurred in 3 persons of Afrikaner ancestry who shared a common haplotype, suggesting a founder effect. Compound heterozygotes exhibited 
a severe phenotype, in keeping with an allele-dosage effect.
Conclusion: PKP2 gene mutations are common in South African individuals with ARVC. Additionally, we describe for the fi rst time an 
allele-dosage effect and a novel founder mutation in Afrikaners in this gene.
Reperfusion injury and PKC: two new kids on the block
J. McCarthy*, A. Lochner#, S. Genade# and L.H. Opie*
*Hatter Cardiovascular Research Institute, Faculty of Health Sciences, University of Cape Town, South Africa
#Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, South Africa
Cardiovascular diseases are predicted to become the major cause of mortality world wide by 2020. 
During or shortly after myocardial infarction (MI), the optimal treatment is rapid restoration of myocardial blood fl ow on the assumption that 
this will limit infarction damage. However, clinical studies during PCI for acute myocardial infarction suggest that up to 45% of cardiac cells that 
should have been saved from ischaemic death rather undergo reperfusion-induced necrosis. This phenomenon is known as reperfusion injury.
Intense research has pioneered three methods of cardioprotection to minimise this injury: ischaemic preconditioning, ischaemic post conditioning 
and remote preconditioning. These cardioprotective mechanisms all activate one or more of the protein kinase C family (PKCs) occurring in 
the cytosol. Only two PKCs are important in cardioprotection: PKCepsilon (PKCε) is cardioprotective and PKCdelta (PKCδ) is deleterious. 
Small and large animal trials illustrated the benefi t of inhibiting PKCδ, leading to a small human trial (DELTA MI) which demonstrated preliminary 
clinical benefi t from PKCδ inhibition at reperfusion after MI - ejection fraction increased to normal values, LV developed pressure improvement 
and decreased infarct size.
Our research focuses on the protective benefi t of increased activated PKCε at the level of the mitochondrion. Mitochondria are more than just 
energy generators for the cell, but also regulate the life and death of the cell. To explore the contribution of activated PKCε to cardioprotection 
we have a transgenic mouse model overexpressing cardiac-specifi c PKCε . These mouse hearts are extremely resistant to acute or chronic 
oxidant stress, exhibiting dramatically reduced infarct size (p<0.03 vs WT) and a robust cardioprotective programme residing in part at the 
mitochondrion. Isolated PKCε mitochondria respire better (PKCε :180 25 vs 11612in the WT, n=8,p<0.02) and produce more ATP after acute 
and chronic oxidant stress (p<0.03 vs WT).
Glucose as cardiac fuel source is cardioprotective, especially during reduced oxygen levels. PKCε hearts preferentially metabolise glucose, 
producing more cardiac work at lower oxygen consumption (1.78 0.1 vs 1.25  1.2 mJ/min/g dry weight, p<0.05). We conclude therefore that 
activated PKCε-mediated preferential cardiac fuel selection might be the source of the robust cardioprotection seen in aPKCε animals. 
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Are all the pulses present? An interesting presentation of aortic coarctation
B.J. Mitchell, F.F. Takawira and J. Joshi 
Department of Paediatric Cardiology, Steve Biko Academic Hospital and University of Pretoria, South Africa
 
Introduction: This case of neonatal coarctation re-emphasises the importance of evaluating the neonates pulses and blood pressures (BPs) 
in all four limbs.
Case study: A 2.5kg male infant was born normally to a 37yr G5P5 mother at 8 months gestation. He was admitted on day 2 of life with 
oedema and respiratory distress with saturations of 85%.  He had minor dysmorphic features - a diagnosis of Noonan syndrome was considered. 
Pulses and BPs were equivalent in all four limbs: 65/35 mmHg.  He was intubated and ventilated with improved saturations of 99%.  
Cardiac echo showed normal intra-cardiac anatomy, a dilated right heart and severe pulmonary hypertension (PAH), with estimated pul-
monary pressures of 60/30mmHg and bidirectional shunting across the patent ductus arteriosus (PDA) and foramen ovale. The aortic 
arch anatomy was suspicious of coarctation in evolution with narrowing of the juxtaductal aorta. No coarctation gradient was present 
however due to the large PDA.  In addition, an aberrant subclavian artery arising distal to the narrowing was seen.
The next morning he had no pulses palpable in the right arm and legs with BP in these three limbs signifi cantly lower : 48/28 (mean 36) mmHg 
than that of the left arm 63/32 (mean 50) mmHg.  The repeat echo showed a small PDA with clear coarctation of the aorta. The PAH 
had resolved.  Due to the clinical fi ndings, the right subclavian artery was thought to be aberrant and arise distal to the site of coarctation. 
This was confi rmed with CT angiography and at surgery.  An end-to-end anastamosis was performed with satisfactory results.
Discussion: Aberrant right subclavian artery (ARSA) accompanies 3% of congenital cardiac defects and 1% of coarctations. Embryologically, 
the RSA develops proximally from the right 4th aortic arch, the right dorsal aorta and the right 7th intersegmental artery distally. In ARSA, 
only the latter remains, connected to the descending aorta. The ARSA can complicate coarctation repair : as the spinal artery arises from 
the subclavian arteries via the vertebral arteries, if both subclavian arteries are clamped, distal hypoperfusion and spinal cord ischaemia 
may occur.  The diagnosis must thus be made pre-operatively to aid operative planning.
Infantile Marfan syndrome: a short tale
B.J. Mitchell, F.F. Takawira and J. Joshi 
Department of Paediatric Cardiology, Steve Biko Academic Hospital and University of Pretoria, South Africa
 
Introduction: Marfan Syndrome is readily diagnosed.  A more severe form, termed infantile or congenital Marfan Syndrome, is associated 
with signifi cant mortality at an early age.  We present a case study of this rare disorder.
Case study: A one-year-old boy presented with a cardiac murmur, recurrent chest infections, failure to thrive and developmental delay. He 
had a worried old man appearance with frontal bossing, dolicocephaly, high arched palate, micrognathia and low-set ears. He had pro-
nounced hypermobility of his joints, pectus carinatum, kyphoscoliosis, arachnodactyly and contractures of the metacarpo-phalangeal joints. 
Ophthalmological examination showed megalocornea and iridodonesis with lens subluxation. His vitals were normal for age. He had cardio-
megaly with an associated apical systolic thrill.  Auscultation confi rmed a 4/6 pansystolic murmur over the apex.  He had mild hepatomegaly 
and a small umbilical hernia. ECG showed mild LVH with LV strain.  His cardiac ultrasound showed a markedly dilated aortic root of 30mm 
with no aortic regurgitation. Aorta annulus measured 14mm. There was mitral and tricuspid valve prolapse with moderate mitral and 
mild tricuspid regurgitation.  On the basis of the clinical examination and sonar fi ndings, a diagnosis of infantile Marfan syndrome was made.  
Discussion: Marfan Syndrome is an inheritable connective tissue disorder involving especially the cardiovascular, musculoskeletal, and 
ocular systems.  Autosomal dominantly-inherited or sporadic mutations in the fi brillin (FBN1) gene on chromosome 15 lead to disruption 
and disarray of collagen and elastic fi bers with increased interstitial ground substance.  Myxomatous thickening and redundancy of the mitral 
and tricuspid leafl ets, and marked elongation of their chordae tendinae, lead to signifi cant valvar insuffi ciency.  Cardiac ultrasound demonstrates 



















the aortic root dilatation that occurs in 80% of cases and evaluates the degree of AV valve regurgitation. Sporadic cases tend to be more 
severe with mutations generally in exons 24-32. Children with these mutations usually die of cardiopulmonary failure in the fi rst few years 
of life.  This severe form has been termed neonatal, infantile or congenital Marfan syndrome. Hyperextensible joints and arachnodactyly are 
a reliable clinical marker of connective tissue disease and with the characteristic facial appearance, the diagnosis of infantile Marfan syndrome 
is readily apparent.  
The Atrial Switch: does it cut the mustard?
B.J. Mitchell, F.F. Takawira, G. Sinyangwe and J.J. Joshi
Department of Paediatric Cardiology, Steve Biko Academic Hospital and University of Pretoria, South Africa
Introduction: The Atrial Switch procedures remain an imperfect solution to a complex condition.  We present a case of obstructed systemic 
venous return following Mustard operation.
Case study: A 2.6kg female patient presented at age 4 weeks with severe cyanosis and respiratory distress. She had dysmorphic features in 
keeping with Goldenhar syndrome. She was supported with Prostaglandin E1 infusion and mechanical ventilation. Echocardiography 
diagnosed d-transposition of the great arteries with intact interventricular septum (TGA/IVS) and a restrictive foramen ovale.  Coronary artery 
anatomy was normal.  She underwent successful balloon atrial septostomy but developed protracted nosocomial sepsis in PICU. Due to 
her fragile state and relatively late presentation, she was not considered a candidate for early Arterial Switch Operation (ASO) and a 
Mustard operation was performed when she was 2yrs old.   
Routine follow-up was uneventful until age 3yrs 3mths when she presented with anorexia, abdominal distension and ascites. Echocardio-
graphy showed marked right heart dilation and turbulence in the superior systemic venous baffl e. Angiography confi rmed narrowing of 
the SVC baffl e, interrupted IVC with azygous continuation and unobstructed pulmonary venous return. Balloon dilation of the obstructed 
baffl e provided only temporary relief and symptoms soon recurred. A balloon-expandable covered stent was therefore positioned across 
the narrowed area and dilated to provide relief of the obstruction. Her symptoms resolved satisfactorily and have not recurred.
Discussion: Correction of TGA/IVS by the Mustard or Senning operations is associated with signifi cant complications and long-term 
morbidity. The right ventricle is anatomically unsuited to the role of systemic ventricle and becomes progressively less functional, with 
increasing tricuspid valve regurgitation and loss of sinus rhythm. Obstruction of the venous return baffl es occurs in 5% of cases. Re-operation 
to relieve baffl e obstruction carries an increased mortality risk especially in small, unstable patients such as ours, thus catheter intervention 
provides an attractive alternative. Serial dilation of the stent can be performed as interim palliation until re-do of the Mustard operation 
or conversion to an ASO is possible. While intra-cardiac stents may complicate baffl e take-down at the time of the ASO conversion, they 
provide valuable time for growth and stabilisation in these patients. 
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An evaluation of NT-proBNP blood levels in HIV positive patients with pericardial effusions
T.J. Naicker, P. Manga and Y. Veriawa
Department of Chemical Pathology, NHLS, Department of Cardiology, Johannesburg Hospital and University of the Witwatersrand, 
Johannesburg, South Africa
 
Aim: To determine the clinical utility of the biochemical marker NT-proBNP in the diagnosis and management of HIV positive patients with 
pericardial effusions.
Methods: 10 patients (all < 60 years of age) admitted to the Johannesburg Hospital with a presumptive diagnosis of pericardial effusion were 
recruited for the pilot study. The diagnosis was deduced from the history, symptoms, physical examination, ECG fi ndings and confi rmed with 
2-dimensional echocardiography. Patients in renal failure, with diffuse myocardial disease, valvular disease and effusions secondary to cardiac 
failure were excluded. Blood for NT-proBNP was sampled on diagnosis and again approximately 48hrs after pericardiocentesis. NT-proBNP 
was measured with a chemiluminescence immunoassay on the Roche Elecsys 2010 analyser (Roche Diagnostics-Hitachi, Germany). Values 
< 125ng/L excluded cardiac dysfunction.
Results: All patients had raised NT-proBNP at presentation with levels ranging between 289 ng/L and 1976ng/L. The levels fell by 20 to 66% 
48hrs post pericardiocentesis.
Conclusions: Echocardiography is a labour intensive procedure and may not be immediately available at regional hospitals. These results 
indicate that NT-proBNP could be a useful diagnostic marker in this setting aiding an earlier diagnosis and hence an improved patient outcome. 
Further investigation is warranted. 
Fasting plasma arginine concentrations and ambulatory blood pressures
C. Naidoo*, A.D. Cromarty#, J. Peters* and G.P. Candy*
*Department of Surgery, Wits Medical School, University of the Witwatersrand, Johannesburg, South Africa
#Faculty of Health Sciences, School of Medicine, Department of Pharmacology, University of Pretoria, South Africa
Stroke, end stage renal failure and heart failure are the consequences of elevated blood pressures which affl ict the African community far 
more than other racial groupings. Arginine is the precursor to the arterial vasodilator nitric oxide (NO), a key cellular messenger and 
mediator of a host of physiological functions. Although supplementation with arginine is known to reduce blood pressure, there have been 
several reports, including our own study, demonstrating elevated fasting plasma arginine concentrations in patients of African ancestry 
with hypertension. This suggests that arginine is available but is either not available for NO formation or the NO formed is degraded or 
cannot mediate vasodilation. There is little baseline data, both locally and internationally, of fasting plasma arginine concentrations and whether 
these affect ambulatory blood pressure profi les. 
Methods: 24 hour ambulatory blood pressures (ABPM) were measured in consenting participants recruited from clinics in the Johannesburg 
area. Fasting blood samples were obtained and frozen until analysed by HPLC/mass-spectrometry. 
Results: Arginine concentrations were elevated in subjects with hypertension and correlated with average diastolic pressures, particularly 
night time DBP (r=0.280; p<0.05). In males of BMI<30kg/m2, arginine correlated with both night time diastolic (r=0.461; p<0.005) and 
systolic pressures (r=0.420; p<0.005). These data are similar to data reported in the literature. Re-analysis of the data, dichotomizing by 
the median arginine concentration (56mol/L), showed differences in the ABPM profi le pattern between the arginine groups.
Conclusion: Plasma concentrations of the NO precursor, arginine are elevated in black South Africans with hypertension and correlated 
with average night time blood pressure particularly in men of lower BMI. As fasting arginine concentrations were elevated in black South 
African subjects with hypertension, further studies are needed to determine whether decreased arginine uptake into endothelial cells or 
NO production/availability contributes toward the increased blood pressure in this high risk population. ABPM profi le patterns differed 
between study participants with higher and lower arginine concentrations.



















An awareness programme to help reduce patient delays in acute myocardial infarction 
Raveen Naidoo* and Karen Sliwa#
*Department of Emergency Medical Care and Rescue, Durban University of  Technology, South Africa
#Department of Cardiology, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa
Introduction: Defi nitive treatment for heart attack is early reperfusion by either primary angioplasty or thrombolytic therapy. The time 
elapsed from the onset of symptoms to reperfusion is directly related to patient outcomes as demonstrated in the GISSI trial more than 
20 years ago. Reperfusion is a time-related intervention. There are three key components to prompt and effective reperfusion therapy: 
addressing patient delay, increasing utilisation of the ambulance service and addressing the prolonged in-hospital treatment delays would 
signifi cantly reduce pain-to-needle times. The patient is most probably the most important factor involved in the delay between the onset 
of AMI and the start of reperfusion treatment. A number of factors, including the type of acute coronary syndrome, the nature and localisa-
tion of the symptoms, the place where the symptoms occurred, the patients interpretation of symptoms and knowledge were associated 
with the patients decision time (Herlitz, Thuresson et al. 2009).   Various registries of patients with acute myocardial infarction have shown 
that the time from symptom onset to hospital presentation was ≥ 4 hours in 50%, > 6 hours in 40% and > 12 hours in 9 – 31%. A study 
in South Africa has shown that the patient took a mean time of 3:32 ± 5:26 hours to call for help and that only 10% (12) patients utilised 
an ambulance service. This implies that for maximum effectiveness, the public should be trained to recognise symptoms early and activate 
the emergency medical services early through a health awareness program via mass media to reduce delay times. The purpose of this 
study was to develop a culturally sensitive and affordable chest pain education program.
Methods: A document study was undertaken on existing chest pain awareness programs in international settings that led to the develop-
ment of a culturally sensitive and affordable chest pain awareness program.
Ethics: Ethical approval was granted by the Human Research Ethics Committee - University of Witwatersrand. 
Results: A poster, an information booklet and a video on heart attack awareness were developed after studying documentation from 
United Kingdom, Canada, Australia and South Africa.
Conclusion: Attempts to change the actions of individuals experiencing AMI symptoms on an ongoing basis must and should continue. 
Structures to facilitate various approaches need to be established for coordination and implementation. Until reperfusion strategies are 
delivered effectively, the promise of reduced morbidity and mortality from AMI will not be realised.
Impact of time to treatment with fi brinolytic drugs in patients presenting with ST- elevation 
myocardial infarction
R. Naidoo*, N. Ranjith#, D. Singh* and N. Castle*
*Department of Emergency Medical Care and Rescue, Durban University of Technology, KwaZulu-Natal, South Africa
#Department of Medicine, Coronary Care Unit, R K Khan Hospital, Durban, KwaZulu-Natal, South Africa
 
Aims: The prompt restoration of myocardial blood fl ow is vital to myocardial salvage and mortality reduction after ST- elevation myocardial 
infarction [STEMI]. Reperfusion is achieved with primary percutaneous coronary intervention (PPCI) or fi brinolytic agents. Due to the 
limited availability of PPCI, fi brinolytic therapy still remains an important treatment modality in managing STEMI. The aims of this study were 
to address the time interval from fi rst patient contact to initiation of fi brinolytic treatment, possible reasons for treatment delay, and complica-
tions arising in those with and without treatment. 
Methods: The study population comprised 120 patients with STEMI presenting to 20 different hospitals in Durban and surrounding regions 
between August to December 2006. Demographic data, time to treatment, reasons for non-treatment, and complications encountered 
during hospital stay and at day 30 were obtained from hospital records and patient interviews.
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Results: The median age of the study group was 58 years with a clear male preponderance [71%]. Sixty fi ve percent received fi brinolytic 
treatment [Streptokinase (58%); Tenecteplase (42%)]. In patients who presented to hospital less than 2 hours from symptom onset [n=9 
(8%)], 78% received fi brinolytic treatment; within  2-6 hours [n=46 (38%)], 63% were thrombolysed, while 65 patients [54%] presented 
greater than 6 hours of whom only 46% were given fi brinolytic drugs. The mean time from symptom onset to fi brinolytic treatment was 8.36 
5.57 hours. The major reasons for patients not given fi brinolytic drugs were late presentation and inadequate facilities for fi brinolysis 
[88%] while 12% were excluded because of standard contraindications to fi brinolytic treatment. The commonest complications observed 
during hospital stay and at 30-day follow-up included cardiac failure [18%], death [14%], recurrence of angina [11%], and recurrent myo-
cardial infarction [4%]. Signifi cantly more patients developed cardiac failure [p = 0.05], if they presented to hospital after 6 hours from 
symptom onset, irrespective of whether they received fi brinolytic treatment or not.
Conclusion: Delay in the administration of fi brinolytic drugs for STEMI results in increased morbidity and mortality. Prompt recognition of 
STEMI and shortening the time interval from fi rst patient contact to initiation of fi brinolytic drug infusion will greatly improve survival. 
Relationship between anatomical and electrical indices of left ventricular hypertrophy, 
derived from cardiac MRI and ECG
Richard Nethononda*,#,**, Barbara Casadei#, Nicola Alder†, Polly Whitworth*,#, Jane Francis*,#, Steffen Pettersen*,#, 
Hugh Watkins# and Stefan Neubauer*,#
*Oxford Center for Cardiac Magnetic Resonance Imaging Research (OCMR), University of Oxford, United Kingdom
#Cardiovascular Medicine Deparment, University of Oxford, United Kingdom
†Center for Statisitcs in Medicine, University of Oxford, United Kingdom
**Division of Cardiology, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa 
Background: ECG is commonly used to screen for left ventricular hypertrophy (LVH), but doubts exist about its accuracy for this purpose. 
Cardiac MRI (CMR) is the gold standard for measurement of LV mass (LVM) and other cardiac parameters.
Objective: To determine the relationship between anatomical and electrical indices of LVH, derived from ECG and CMR in a large cohort 
with high prevalence of this condition.
Methods: 430 subjects from the Oxford Family Blood Pressure cohort were recruited over a 2-year period. Medical history, demo-
graphic and anthopometric data, 24h ambulatory blood pressure (ABP) and 12-lead ECGs were obtained. CMR was used to measure LV 
parameters and chest diamensions. One blinded observer manually analysed ECGs to obtain the QRS duration, Sokolow-Lyon, Cornell, 
12-lead sum of QRS voltages and LV mass. Genders were compared using chi-squared and t-tests for categorical and continuous data, 
respectively. Pearson correlation and the Bland-Altman methods were used to analyse the relationship between ECG indices and CMR-
derived LV parameters.
Results: Age, BMI, prevalence of diabetes and hypertension, and the distance from the epicardium to skin surface position of lead V1 were 
not signifi cantly different between males and females, whereas height, weight, BSA, 24h ABP, all chest dimensions, all ECG indices, and CMR-
derived LVM and wall thickness were larger in males. ECG-derived indices of LVH were moderately correlated with CMR LVM and wall 
thickness in males; in females, however, the strength of these correlations was weaker. Agreement between ECG- and CMR-derived LV 
mass was poor.
Conclusion: The ability of the ECG to estimate LV mass and detect anatomical LVH is limited, particularly in females. These fi ndings have 
implications for current guidelines on management of hypertension, as risk straticifi cation based on ECG indices of LVH only may be inappro-
priate for many, particularly females. 



















The predictors of effusive constictive pericarditis in patients with confi rmed tuberculous 
pericarditis
Mpiko Ntsekhe
The Cardiac Clinic, Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa
Background: Constrictive pericarditis is a frequent late complication of tuberculous [TB] pericarditis. Effusive constrictive pericarditis (ECP) 
is thought to be a precursor of constrictive pericarditis. It occurs when a hemodynamically signifi cant pericardial effusion and visceral peri-
cardial constriction co-exist. The diagnosis requires measuring the pre and post pericardiocentesis cardiac and intra-pericardial pressures; 
echocardiography is insensitive and non-specifi c. The syndrome remains unrecognised in many patients with pericardial effusion until they 
present later in their course with constriction and heart failure. Although ECP is a rare manifestation of idiopathic pericarditis, the Initiative 
for the Investigation and Management of Pericarditis In Africa (IMPI) registry has shown that it is a common presentation of TB pericarditis. 
We set out to determine the predictors of ECP in patients with TB pericardial effusions. 
Methods: Between Dec ‘06 and July ‘08 consecutive patients with large TB pericardial effusions were enrolled in the IMPI registry. At 
baseline all patients had full clinical, CXR, ECG, full blood count, serum chemistry, HIV, CD4 count and pro-BNP. Pericardial fl uid volume, 
cell count, chemistry and cultures were recorded. Pre and post pericardiocentesis right atrial and intra-pericardial pressures were measured 
and the presence or absence of tamponade was determined.
Results: 68 consecutive patients with confi rmed tuberculosis and complete data were included in the analysis. Median [IQR] age was 31 
[28-41], 56% were male, 74% were HIV infected and 50% were TB culture positive. The mean volume of fl uid drained was 971 cc. 53% had 
ECP. By univariate logistic regression analysis age, opening RAP [>15mmHg] and opening IPP were signifi cantly associated with the risk of 
ECP. However only the opening RAP remained signifi cant in the fi nal multivariate model; odds ratio 15.4, 95% CI 2.4-99.6 [p=.004.].
Conclusions: In this fi rst and largest study of its kind, we show that a very high right atrial pressure, in patients with a hemodynamically 
signifi cant tuberculous pericardial effusion, is associated with co-existing constriction of the visceral pericardium or ECP. These fi ndings 
may have implications for identifying patients who are at very high risk for developing constrictive pericarditis despite completion of anti-
tuberculosis therapy.
Myocardial rupture with left ventricular pseudoaneurym formation complicating 
staphylococcal pericarditis 
A. Nzimela, E.G.M. Hoosen and N.J. Buckels
Paediatric Cardiology, Inkosi Albert Luthuli Central Hospital, Durban, South Africa
A previously well 12 year old female presented to our cardiology unit with signs of congestive cardiac failure. She had been admitted to 
the referring hospital for 3 weeks prior to transfer and was managed for suspected septic arthritis of the right knee, for which she eventually 
had incision and drainage of a right thigh abscess from which staphylococcus aureus was cultured.  She had been on intravenous cloxacillin 
for two weeks. On examination, she was ill, pyrexial and in respiratory distress. Pulses were small volume, jugular venous pressure was raised, 
a 12 cm tender hepatomegaly was palpated and the cardiac apex could not be localised. A large right pleural effusion and cardiomegaly were 
evident on chest radiography.   
The echocardiogram demonstrated a massive pericardial effusion with signs of tamponade. Urgent pericardiocentesis was performed and 
a pyopericardium confi rmed. This was followed by open drainage for pyopericardium, the pericardial space was washed out with saline and 
specimens sent for histology and culture from which cloxacillin sensitive staphylococcus aureus was again cultured. A pericardial drain was 
left in situ from which, three days later, bleeding was noted. A repeat echo showed on colour fl ow mapping fl ow from the left ventricular 
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posterior wall into a 30mm pseudoaneurysm. A CT angiogram confi rmed the echocardiographic fi ndings and an uneventful resection of 
the false aneurysm was performed on the same day.
The child made a complete recovery with complete resolution of the effusion on follow up.  
A pseudoaneurysm of the ventricle is a contained myocardial rupture, its wall being lined by pericardium and mural thrombus. It is most 
commonly seen post myocardial infarction. Myocardial rupture following septic pericarditis is exceedingly unusual with few cases reported in 
the literature. 
Outcomes of off-pump Coronary Artery Bypass Grafting (CABG) and Coronary Artery 
Bypass Grafting (CABG) versus Cardiopulmonary Bypass (CPB) in a South African patient 
population
C.K.P. Ofoegbu and J. Brink
Chris Barnard Division of Cardiothoracic Surgery, University of Cape Town/Groote Schuur Hospital, South Africa
Introduction: Off-pump coronary artery bypass grafting (OPCAB) was developed to avoid the deleterious effects of CPB. Current literature 
reveals some peri-operative advantages of OPCAB, with few studies detailing these in Africa.  We review our institutional experience with 
both approaches to determine pre-operative characteristics, short and mid-term outcomes in a developing country.  
Patients and methods: A retrospective review of patients operated by the 2 surgeons in the department between January 2001 and 
December 2007. Fields determined include: pre-operative patient characteristics, intra-operative data and post-operative variables 
(intensive care unit (ICU) stay, blood loss, use of blood products, complications, death and follow-up). 
Results: Records of 342 patients were reviewed. Of these, 199 had OPCAB and 143 had CABG-CPB. There were no signifi cant differences 
between the 2 groups for age and CAD risk factors, with CAD family history commoner in OPCAB patients (p = 0.009). There were no 
signifi cant differences in incidence of co-morbidities, NYHA class, left ventricular ejection fraction (LVEF) and proportion of urgent/
emergency surgery. The mean number of vessels grafted was 3.31 and 3.45 in OPCAB and CABG-CPB groups respectively (p= 0.145).
The intra-operative conversion rate from OPCAB to CABG-CPB was 2.5%. The mean ICU duration for OPCAB and CABG-CPB patients 
was 80.7 hours and 104.1 hours respectively (p= 0.181). The mean mechanical ventilation duration in OPCAB and CABG-CPB patients 
was 22.3 hours and 38.3 hours respectively (p= 0.091). The mean ICU blood loss in OPCAB and CABG-CPB patients was 808.5 mls and 
988.2 mls respectively (p=0.0029). Mean red cell (RBC) transfusion was 1.72 units and 2.66 units in OPCAB and CABG-CPB patients 
respectively (p=0.03). The CABG-CPB patients had more post-operative ward stay than OPCAB patient (7.4 versus 5.5 days, p= 0.01). 
The peri-operative mortality rate was 3% and 9% in OPCAB and CABG-CPB patients respectively (p= 0.016). There was no signifi cant 
difference in major adverse cardiac events (MACE) during the follow up period (p= 0.605).
Conclusion: The pre-operative characteristics in both groups were similar. There was less ICU blood loss, less usage of RBCs and less 
hospital stay in the OPCAB group. Peri-operative mortality was signifi cantly worse in the CABG-CPB group, but no difference in MACE 
during follow up.



















Prevalence of Asymptomatic Left Ventricular Systolic Dysfunction in Hypertensive 
Nigerians: Echocardiographic study of 832 subjects
Okechukwu S. Ogah, Rufus O. Akinyemi, Gail D. Adegbite, Oscar I. Udofi a, Sunday B. Udoh, Julius O. Adesina, 
Oluwaseun S. Ojo, Albert A. Alabi, Julius K.L. Osinfade, Roseline F. Ogundipe, Ayodele O. Falase
Department of Medicine, Federal Medical Centre, Idi-Aba, Abeskuta, Ogun Stat, Nigeria
Introduction:  We sought to determine the prevalence of echocardiographically determined   left ventricular systolic dysfunction in asymptomatic 
hypertensive subjects seen in Abeokuta, Nigeria.
Methods: Echocardiography was performed in 832 consecutive hypertensive subjects referred for cardiac evaluation over a three-year period. 
Results: Data was obtained in 832 subjects, (50.1% women), aged 56.012.7 years (men 56.913.3, women 55.012.0, (range 15-88 years). 
The prevalence of left ventricular systolic dysfunction was 18.1% in the study population (mild LVSD = 9.6%, moderate LVSD = 3.7%, 
and severe LVSD = 4.8%). In a multivariate analysis, male gender, body mass index, LV mass were the predictors of LVSD.
Conclusion:  We conclude that screening for LVSD among hypertensive subjects who are at risk of heart failure is feasible and has substantial 
yield, even among patients without symptoms of heart failure. In light of the low cost of screening and the available therapies to prevent 
progression of LVSD to overt HF, we suggest limited echocardiography (where available) especially for patients with marked abnormalities 
on their 12 lead electrocardiographs. A controlled clinical trial of screening high-risk hypertensive patients appears to be justifi ed.
Pattern of prescription of anti-hypertensive medications in a tertiary health care facility in 
Abuja, Nigeria 
D.B. Ojji*, A.A. Akor#, O.S. Omonua# and A.O. Falase†
*Cardiology Unit, Department of Medicine, University of Abuja Teaching Hospital, Gwagwalada, Abuja
#Department of Medicine, University of Abuja Teaching Hospital, Gwagwalada, Abuja
†Cardiology Unit, Department of Medicine, University College Hospital, Ibadan
 
Introduction: There have been marked changes in the pharmaco-therapy of hypertension over the years with a trend towards the use of 
calcium channel blockers, angiotensin converting enzymes, angiotensin receptor blockers and low dose thiazide diuretics. In Sub-Saharan 
Africa, there is the original belief that anti-hypertensive therapy still centres on thiazide diuretics, beta blockers and centrally acting medica-
tions with little or no use of newer medications like calcium channel blockers, angiotensin converting enzymes and angiotensin receptor 
blockers.  We therefore decided to look at anti-hypertensive prescription pattern in a tertiary centre in Abuja, Nigeria, to see how it conforms 
to current trends.
Methods: Five-hundred and fi fty-nine (559) hypertensive subjects presenting newly at the Cardiology Unit of University of Abuja Teaching 
Hospital over a three-year period were studied. Demographic, clinical and baseline blood analysis data were obtained.
Result: Male subjects constituted 49.7% of the study population while female constituted 50.3%. The mean age of the subjects was 
49.7412.21years, mean arterial blood pressure was 111.79 17.90mmHg while the mean fasting blood sugar was 5.922.97mmol/l.
Calcium channel blockers were the most frequently prescribed anti-hypertensives in 66.9% of the study population followed by low dose 
thiazides in 54%, angiotensin receptor inhibitors in 47.8% and beta blockers in 34.2% of cases. Centrally acting medications were prescribed 
in only 5.01% of cases. Single-pill combination either alone or in combination with other anti-hypertensive medications were prescribed in 
55.3% of cases, with combination of low dose thiazide and potassium sparing diuretic (amiloride) in 35.2%, Lisinopril and low dose thiazide 
combination in 12.5% and angiotensin receptor blockers and low dose thiazide combination in 5.01% of cases. Calcium channel blockers 
(CCBS) based combinations constituted the most frequently used multiple drug combinations with CCBS and thiazides in 39.4% of cases, 
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CCBS and angiotensin receptor inhibitors in 18.2%, CCBS and beta blockers in 9.48% and CCBS and angiotensin receptor blockers in 5.72% 
of cases. 94.6% of the subjects required more than one medication.
Conclusion: Anti-hypertensive pharmacotherapy at the University of Abuja Teaching Hospital, Nigeria, compares favourably with the current 
trends in the prescription pattern of anti-hypertensive medications.
Atropine in the EP lab: not a discarded drug; rather, a useful adjunct in diffi cult tachycardia 
induction in young patients with exercise related palpitations
A. Okreglicki and A. Chin
Cardiac Clinic, Groote Schuur Hospital, Cape Town, South Africa
Introduction:  Electrophysiological studies (EPS) are occasionally indicated on the basis of history of palpitations alone without documentation 
tachycardias.   Typically this occurs in young patients with infrequent episodes only during exercise.  At EPS of such patients, tachycardia may 
remain non-inducible unless extra-ordinary measures are attempted including drugs such as catecholamines. Atropine, often relegated to 
dealing with bradycardia associated with vasovagal reactions, is a useful tool for initiating tachycardia in the EP laboratory.
Aim: To review the cases where atropine played a pivotal role during EPS for rapid palpitations.
Methods and results: Four athletes, with only exercise related paroxysmal palpitations and no documented tachycardia who had EPS were 
reviewed:  3 males, 1 female, aged 20, 22, 31 and 32, competitive extreme athletes, a professional cyclist and a squash player.  In all, EST and 
prolonged ECG recordings had revealed no abnormal arrhythmias.  
Baseline EPS, done unsedated, off medications for 1 week, showed no evidence of accessory pathways and no tachycardia with programmed 
stimulation. In none was dual AV nodal (AVN) physiology at baseline demonstrated. EPS and induction of tachycardia were repeated 
with increasing doses of catecholamine infusion.  On intravenous adrenaline at 0.06  to 0.18 microgram/kg/min no sustained tachy-
arrhythmia occurred.  In 1 patient, dual AVN physiology was demonstrated.  1mg bolus of intravenous atropine sulphate was given to all.  No 
spontaneous abnormal tachycardias occurred. In all 4, there was a signifi cant shortening of the AVN effective refractory period. Rapid 
atrial pacing induced arrhythmias in all: AV nodal re-entry tachycardia (AVNRT) in 2, unifocal atrial tachycardia (AT) in 1 and multiple 
monomorphic atrial tachycardias in 1.  Radiofrequency ablation was performed. At the end of the procedure, re-inducibility was again 
tested using the drugs.
Conclusion: In patients with exercise related palpitations, and non-inducibility at EPS, high dose catecholamine infusion may be insuffi cient 
to initiate tachyarrhythmia.  Unless, parasympathetic withdrawal is achieved, which occurs at peak exercise, and simulated in the EP laboratory 
by administration of atropine, the tachycardias may remain non-inducible and the EPS inconclusive.  Atropine, as demonstrated by signifi cant 
improvement in baseline electrophysiological parameters, may abolish the rebound increased vagotonia during catecholamine infusion 
causing non-inducibility. Therefore, atropine should not be discarded but rather considered earlier in routine EP studies.



















The risk factor profi le of a local community in KwaZulu-Natal: a preliminary analysis
R. Prakaschandra
Department of Biomedical and Clinical Technology, Durban University of Technology, KwaZulu-Natal, South Africa
 
It is well documented that worldwide, immigrant Asian Indians are reported to have higher rates of coronary heart disease [CHD] than the 
native populations of their adopted countries.  Furthermore, premature CHD is increasingly common in this group. The risk factor profi le of 
this community in Phoenix, KwaZulu-Natal, has been poorly studied.
Aims/objectives: To determine the major risk factors for cardiovascular disease (CVD) in the Phoenix community. To determine the preva-
lence of metabolic syndrome (MS) in this community. 
Method: A randomised sample was selected for study and stratifi ed into gender and 6 age groups (15-24, 25-34, 35-44, 45-54 55-64 and 
>65). The WHO STEPS questionnaire was administered to each subject, and demographic and behavioural information was recorded. 
Further physiological, biochemical and anthropometric measurements were done at the Lifestyle Centre at Inkosi Albert Luthuli Hospital. 
Descriptive statistics were performed for biochemical and anthropometric parameters. The presence of metabolic syndrome (MS) was 
determined using the National Cholesterol Education Programme Adult Treatment Panel III [NCEP ATP III] and International Diabetes 
Federation [IDF] criteria.
Results: A total of 1419 participants have been studied, of which 72% were women, and 28% were men. Impaired fasting glucose was 
present in 3% of the 15-24 age group, and increased to 19% in the 35-44 age group. Elevated total cholesterol (>5.18mmol/L) was observed 
in 41% of the  25-34 age group,  with this group also  comprising the highest percentage of subjects (20%) with abnormal HDL 
(< 1.0mmol/L).  There was a 24% prevalence of MS in males and 44% in females when the NCEP criteria was applied; with an almost 
10% increase with the IDF criteria. MS was present in 7% of the 15-24 age group, and 23% in the 25-34 year group. There was a steady 
rise after that to 57% in the 55-64 year old group.
Conclusion: There is a very high prevalence of MS in both men and women in this randomised sample. Age-related trends show that the 
risk factors starts as early as 15 years, with a sharp increase by the fi rst quintile. The high prevalence of metabolic syndrome in our 
young participants does indeed herald the earlier onset of accelerated atherosclerotic disease in these subjects.
Heart sound segmentation and classifi cation using neural networks
E. Pretorius*, O.M. Strydom*, W. Schoonbee#, M. Blanckenberg#, C. Scheffer#, P.R. Fourie*, M.L. Cronje* and 
J. Lawrenson†
*Diacoustic Medical Devices, Stellenbosch, South Africa
#Engineering Department, University of Stellenbosch, South Africa
†Red Cross Children’s Hospital and University of Stellenbosch, South Africa
 
Aim of study: The aim of this study was to develop a heart murmur screening system that can aid non-specialists to make informed referrals 
and to decrease the number of unnecessary referrals, while also aiding specialists with less auscultation experience to make a diagnosis with 
higher confi dence.
Methods: To evaluate the algorithms, both the heart-sounds and electrocardiograph (ECG) of 400 patients were recorded in a clinical 
environment at the four main auscultation locations, namely; aortic, pulmonic, tricuspid and mitral areas. The recordings were made using a 
WelchAllyn Meditron stethoscope. All the patients had an echo cardiograph done by a cardiologist to determine the correct diagnosis. 
The dataset contains 222 pathological, 45 functional and 133 normal (no murmur present) patient recordings. 
Each heart signal was noise fi ltered and split into heartbeats using the ECG as reference and 5 representative beats were selected. These 
beats were segmented into s1, systole, s2 and diastole regions and feature vectors calculated. Features were chosen to include the signal 
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shape, time-frequency content and signal statistics. To evaluate the feature selections, a 2-layer neural network was used to classify signals 
as either normal or pathological. To determine the sensitivity and specifi city of the system, the Jack-Knife method was used with a test set 
size of 1, 5 and 10 signals. 
Results: Initial results, fi rstly considering VSD’s, obtain performances of 82% sensitivity and 99% specifi city ratings. Other pathologies need 
to be optimised since sensitivities were lower using the same type of features.
Conclusion: Normal heart-sounds have low frequency components with large amplitudes at s1 and s2 and less frequency information in 
the systole and diastole regions. Murmurs on the other hand, contain higher frequency components that usually have lower amplitudes, 
making it diffi cult for the human ear to detect. This and the fact that clinical conditions are rarely noiseless, makes a diagnosis much more 
diffi cult. The proposed system shows that automatic auscultation is possible and can perform well in real clinical conditions to aid both 
specialists and non-specialists to make improved confi dent decisions.
Surgical decision making in patients with ischaemic mitral regurgitation undergoing CABG: 
more opinion than evidence? A systematic review
V. Pretorius, Y. Liang, R. Tsuyuki and D.B.Ross
Division of Cardiac Surgery, University of Alberta, Canada 
Objectives: It is unclear if patients presenting for coronary artery bypass grafting (CABG) with ischaemic mitral regurgitation (MR) should 
undergo CABG only or be offered CABG and mitral valve (MV) surgery. We aimed to quantify the effects of CABG and MV surgery (repair 
or replacement) compared to CABG only by conducting a systematic review of the literature. Specifi c outcomes included: Overall 
survival, Thirty-day mortality, NYHA functional class. 
Methods: To identify relevant studies, a medical librarian searched the following computerised bibliographic databases:  MEDLINE, EMBASE, 
SCOPUS, PASCAL, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and Dissertation Abstracts. Studies 
were included if they compared the two groups, reported the outcomes of interest and provided primary data. Methodological quality 
was assessed using the Newcastle-Ottawa method. Studies were combined using the log Hazard Ratio (HR) for survival, the Risk Difference 
(RD) for 30-day mortality, and the Weighted Mean Difference (WMD) for the change in NYHA functional class. 
Results: The search identifi ed 1580 studies; 117 were examined for inclusion. Thirteen studies (2591 patients) were included. Study designs 
included retrospective cohort (n=11) and case-control (n=2) studies. The pooled unadjusted HR for overall survival was not signifi cantly 
different between the two treatment groups (HR=1.13; 95%CI:0.93,1.37 I2=27%). Subgroup analysis by study design, quality or period failed 
to demonstrate a signifi cant difference between treatment groups. Sensitivity analysis comparing only studies where the MR grade was 
the same in both groups prior to surgery found no signifi cant difference in overall survival (HR=0.98; 95%CI:0.55,1.73).
For 30-day mortality no signifi cant RD between the two groups was seen (RD=0.05; 95%CI:-0.01, 0.10; I2=64.9%). Subgroup analysis 
revealed that high quality studies favored CABG only with a Number Needed to Treat of 9.09 (95% CI 5.56, 33.33). 
Change in NYHA functional class signifi cantly favored CABG and MV surgery (WMD=0.66; 95%CI:0.05,1.27). Sensitivity analysis revealed 
that for studies where the MR grade was the same between the two treatment groups the pooled estimate (WMD=0.93; 95%CI:0.05,1.81) 
was in favor of CABG and MV surgery.
Conclusions: A systematic analysis of the existing literature cannot elicit the best treatment for patients with ischaemic MR undergoing CABG 
surgery. A randomised controlled trial is required. 



















The role of b-adrenergic receptors and prosurvival kinases in the cardioprotective effects 
of Beta Preconditioning (BPC)
R. Salie*, A. Lochner# and J.A. Moolman#
*Medical Research Council of South Africa, South Africa
#Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, South Africa
Transient pharmacological stimulation of beta-adrenergic receptors elicits cardiac protection against ischaemia (beta-adrenergic pre-con-
ditioning) (BPC) by unknown mechanisms. 
Aim: To determine the involvement of adrenergic receptors and signaling pathways in the mechanism of BPC. 
Methods: Isolated perfused rat hearts were subjected to 35 min regional ischaemia / reperfusion and preconditioned with 5 min isoproterenol 
(Iso) 10-7 M (BPC). Selective beta-1, -2, -3 AR blockers CGP 20712A (300 nM), ICI 118551 (50nM), SR 59230A (100 nM), or beta-2, -3 AR 
agonists, formoterol (1 nM), BRL 37344 (1uM), respectively were applied to BPC as well as non-preconditioned hearts (NPC). Inhibitors of 
ERK (PD 098,059; 10 M), PI3-K (Wortmannin; 100 nM), PKA (Rp-8cAMP; 16 M) or NOS (L-NAME, 50M) were administered prior to 
ischaemia / at reperfusion. Pertussis toxin (Ptx, 30 g/kg) was given ip 48h prior to experiments. Infarct size (IS) was determined using 
TTC staining. Hearts were freeze-clamped at reperfusion for Western blot determination of PKB / ERK.
Results: BPC or Beta-2 AR stimulation resulted in signifi cantly smaller IS compared to NPC hearts (23.251.62; 20.70.9 vs 40.01.5, 
p<0.001). CGP 20712A and ICI 118551 abolished BPC completely (40.61.2 and 41.51.6, respectively), whereas beta-3 AR inhibition / stimulation 
or NOS inhibition had no effect. PKA inhibition abolished BPC (40.361.65 vs 23.351.62, p<0.001) while Ptx had no effect. Wortmannin or 
PD 098,059 abolished BPC (401.65% and 441.7%, respectively). Wortmannin signifi cantly decreased activation of PKB (2.780.16 vs 0.71 
0.17, p<0.01) and ERK p44 (3.550.32 vs 2.160.17, p<0.05) / p42 ERK (2.670.13 vs 1.56.09, p<0.05), whereas PD 098,059 decreased ERK 
p44 / p42 activation.
Conclusion: Cardioprotection of B-PC involves beta-1 and -2 AR but not beta-3 AR. Beta-2 AR stimulation indicated similar cardioprotective 
effects to that of BPC. PKA activation via Gs may play a role. PKB and ERK p44 / p42 activation during triggering and reperfusion is essential 
for cardioprotection.
Crystal methamphetamine use and myocardial pathology
Lior Y. Sareli and Anton F. Doubell
Division of Cardiology, Department of Medicine, University of Stellenbosch and Tygerberg Hospital, South Africa
Introduction: Methamphetamines (MAP) use has been linked to tachyarrhythmias, myocardial injury due to coronary thrombosis and/or 
vasospasm, pulmonary hypertension, prolonged QTc and cardiomyopathy. Our aim was to assess the occurrence of myocardial pathology 
with MAP abuse in the acute and chronic setting. 
Methods: Twenty eight study and 25 control participants younger than 45 with no prior history of cardiovascular pathology were recruited. 
Study participants had a positive MAP use history (chronic abuse) or a positive MAP urine sample (acutely intoxicated) and no previous 
cocaine use. Controls had ejection fractions >55%, no prior history of MAP and cocaine use and MAP/cocaine negative urine samples. 
A cardiovascular examination, electrocardiogram, echocardiogram, troponin I level (study group only), urine sample for cocaine and MAP 
and a questionnaire on previous drug use was obtained in all participants. The measured parameters in the study and control groups 
were compared. 
Results: The measured parameters did not differ statistically between the study and control groups although there was a trend towards 
chamber enlargement and higher pulmonary pressures with MAP abuse. Three MAP abusers presented acutely, 1 with a dilated cardio-
myopathy (DCMO) and 2 with ST elevation myocardial infarcts (STEMI). One of the STEMIs occurred 3 days after a MAP binge. Angio-
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graphy in the STEMI patients revealed unobstructed coronary arteries and the infarctions were attributed to vasospasm and/or thrombosis. 
There was no correlation between amounts of drug used (MAP use days) and changes in measured parameters.
Conclusion: MAP use may manifest with serious cardiovascular complications including STEMI and DCMO. Acute intoxication with MAP does 
not always present with identifi able electrocardiography, echocardiography and troponin I abnormalities and the cumulative dose of MAP 
use does not predict cardiovascular involvement. However, severe cardiovascular events may be related to MAP binges. Management of 
a STEMI in MAP abusers must address the underlying pathophysiology of vasospasm and/or thrombosis.
Anthracycline-induced-cardiac-myopathy 
Balindiwe J.N. Sishi*, Jacques van Rooyen# and Anna-Mart Engelbrecht* 
*Department of Physiological Sciences, University of Stellenbosch, South Africa
#Cape Peninsula University of  Technology, South Africa
Anthracyclines, in particular Doxorubicin (DXR), are some of the most effective anti-cancer treatments ever developed. Their clinical use 
however is limited due to their signifi cant cardiotoxic effects, highly believed to be caused by the generation of ROS amongst others. 
Although the underlying biochemical mechanisms remain largely undefi ned, it has recently been shown that DXR stimulates ubiquitin-
proteasome system (UPS)-mediated proteolysis by acting on the ubiquitination machinery and the proteasome. While the concept of muscle 
atrophy via the UPS is well established in skeletal muscle, we set out to determine whether the same is true in cardiac muscle under the 
context of DXR-induced cardiotoxicity.
Material & methods:  Male Wistar rats ( 300g body weight) were injected with 2mg/ml/kg DXR solution for a period of 3 weeks. After 3 
weeks of daily treatment, the animals were sacrifi ced, their hearts removed and frozen in liquid nitrogen for subsequent analysis through 
Western blotting using phospho-specifi c and total antibodies.
Results & discussion: The main fi ndings of this study are that the ubiquitin E3 ligase protein expression for both MAFbx/Atrogin-1 and 
MuRF-1 were signifi cantly increased when compared to the control counterparts. In addition, SAPK/JNK phosphorylation also appeared to 
increase. The FoxO subfamily of forkhead transcription regulates gene expression of MAFbx/Atrogin-1 and MuRF-1 thus suggesting a 
common regulatory pathway of both ligases. In contrast to our study, cardiac atrophy induced by heterotopic transplantation of the rat 
heart resulted in decreased levels of the ubiquitin ligases. Increased SAPK/JNK phosphorylation was expected, as DXR triggers ceramide 
production as well as apoptosis. This phenomenon has been observed by others proposing a dose-dependent increase.
Conclusion: The UPS is the major pathway of non-lysosomal degradation of intracellular proteins. From the very few studies conducted on 
the UPS in relation to cardiotoxicity, what can be gathered is that this system appears to be functionally active to a different extent in the 
initiation, progression and complication of cardiac myopathy.



















Bromocriptine promotes recovery of cardiac function and survival in patients with PPCM-
proof of concept study
K. Sliwa*, K. Tibazarwa†, L. Blauwet**, E. Libhaber*, J.P. Smedema¥, A. Becker* and D. Hilfi ker-Kleiner#
* Soweto Cardiovascular Research Unit, Department of Cardiology, Chris Hani Baragwanath Hospital, University of the Witwatersrand 
Johannesburg, South Africa
#Medizinische Hochschule Hannover, Department of Cardiology and Angiology, Hannover, Germany
†Groote Schuur Hospital, University of Cape Town, South Africa
**Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota, USA 
¥Netcare N1 City Hospital, Cape Town, South Africa
Background: Peripartum cardiomyopathy (PPCM) has a poor prognosis and a high mortality (9-30%). We demonstrated that mice with a 
cardiac specifi c knockout for the signal transducer and activator of transcription-3 (STAT-3) develop PPCM. Treatment with bromocriptine 
(BR), a dopamine-D2 receptor antagonist that inhibits prolactin secretion, completely prevented PPCM in these mice. A few case reports 
in humans suggest that BR may also have benefi cial effects in PPCM patients. 
Aim: To assess the effi cacy of BR on the clinical parameters and recovery of left ventricular (LV) function in symptomatic patients with 
newly diagnosed PPCM presenting within the fi rst month after child birth.  
Methods: This was a proof-of-concept prospective single centre randomised study of women with newly diagnosed PPCM receiving 
standard care including ACE-inhibitors, beta-blockers, and diuretics (PPCM-Std, n=10) versus standard care plus BR 2.5 mg bid for 2 weeks 
and 2.5 daily for 4 weeks (PPCM-BR, n=10).  The 6 month outcome of their offspring (n=21) was also studied, as mothers receiving BR 
could not breastfeed their children. Clinical assessment, echocardiography and measurement of prolactin were done at baseline and 6 months 
post diagnosis. Cardiac MRI was performed in PPCM-BR patients to identify thrombus formation due to BR therapy.  
Results: There was no signifi cant difference in baseline characteristics between the two study populations.  PPCM-BR patients had signifi -
cant recovery of LV systolic function (p=0.006), reduction of mitral regurgitation, and improvement in parameters of LV diastolic function 
compared to PPCM Std patients (Table).  Four patients in the PPCM-Std group died versus 1 patient in the PPCM-BR group.  There was no 
signifi cant difference between prolactin levels in the two groups either at baseline or at 6 months.  No thromboembolic events were 
reported.  There was no difference in outcome between the children of PPCM-BR mothers versus children of PPCM-Std mothers.
Conclusions: The addition of bromocriptine to standard heart failure therapy improved LV systolic and diastolic function as well as survival 
in patients with newly diagnosed PPCM.  No detrimental effect on the children that could not be breastfed was observed in this cohort.  
Comparing PPCM-BR (6 months) to PPCM-Std (6 months)
*Value = mean + 1 SD
EF, % 28 + 9 58 + 11 28 + 9 26 + 11 0.006
Mitral ERO, cm2 0.45 + 0.13 0.11 + 0.03 0.44 + 0.18 0.34 + 0.18 0.02
TDI E medial, m/sec 7.0 + 1.3 12.4 + 2.4 6.5 + 1.1 7.3 + 2.5 0.04
TDI E lateral, m/sec 7.2 + 1.1 12.4 + 2.5 6.6 + 1.0 7.3 + 2.5 0.02
 PPCM-BR  PPCM-BR PPCM-Std PPCM -Std p value
 Baseline*  6 months* Baseline* 6 months*   
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Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African 
adults: Insight from the Heart of Soweto study
K. Sliwa*, Melinda Carrington**, Bongani Mayosi†, Elias Zigriades**, Robert Mvungi** and Simon Stewart#
* Soweto Cardiovascular Research Unit, Department of Cardiology, Chris Hani Baragwanath Hospital Soweto, University of the Witwatersrand 
Johannesburg, South Africa
#Preventative Cardiology, Baker Heart Research Institute, Melbourne, Australia 
†Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa
**Division of Cardiothoracic Surgery, Johannesburg Hospital, South Africa
Background: Little is known on the incidence and clinical characteristics of newly diagnosed rheumatic heart disease (RHD) in adulthood from 
urban African communities in epidemiologic transition and their need for surgery.
Methods: Chris Hani Baragwanath Hospital services the black African community of 1.1 million people in Soweto, South Africa. A prospective, 
clinical registry captured data from all de novo cases of structural and functional valve disease (VD) presenting to the Cardiology Unit during 
2006/2007. We describe in detail all cases with newly diagnosed RHD. 
Results: There were 4005 de novo presentations in 2006/07 and 960 (24%) had a valvular abnormality. Of these, 344 cases (36%) were 
diagnosed with RHD. Estimated incidence of new cases of RHD for those aged > 14 years in the region was 23.5 cases/100,000 per annum. 
Most were black African females (n = 234 -68%) with a similar age profi le to males (median 36 [interquartile range 26 50] years versus 
37 [interquartile range 20 50] years. The predominant valvular lesion (n = 204 - 59%) was mitral regurgitation (MR), with 48 (14%) and 
43 (13%) cases, respectively, having combination lesions of aortic plus MR and mixed mitral VHD. Impaired systolic function was found in 
53/204 cases (26%) of predominant MR and in 35/126 cases (28%) with predominant aortic regurgitation. Elevated right ventricular systolic 
pressure > 35 mmHg (88 cases), atrial fi brillation (34 cases) anemia (27 cases) were found in 26%, 10% and 8% of all 344 RHD cases, 
respectively. Subsequent valve replacement/repair was performed in 75 patients (22%). Of these, 18 patients (24%) were readmitted for 
bacterial endocarditis within 30 months. 
Conclusion: These data reveal a high incidence of newly diagnosed RHD within an adult urban African community. As the majority of 
cases were middle aged or older, these data suggest the burden of RHD extends well beyond childhood.
Cardiac complications of Morquios syndrome
H.D. Solomons
Meiring and Partners Pathology Practice, Benoni, South Africa
Morquios syndrome is a rare type of mucopolysacharidosis (type iv) which becomes evident when the affected infant starts to walk. the 
condition is marked by severe dwarfi sm especially of the torso, short neck, prominent sternum, dorsolumbar kyphosis, genu valgum, fl at feet 
and wadling gait. In contrast to Hurlers syndrome the mental retardation is slight to normal. They get aortic valve disease, specifi cally aortic 
regurgitation. To make the diagnosis one picks up keratan sulfate in the urine. There is a type a and a type b form of the disorder. They also 
get cloudy cornea and spinal malalignment. Hypoplasia of the odontoid causes atlantoaxial subluxation, producing myelopathic changes.
In a nut-shell the internal organs continue to grow while the skeletal system stops growing. A good example of this was in the movie The Mighty 
Freak. Most die of congestive cardiac failure related to aortic regurgitation and compression of the heart! On auscultation they characteristically 
get early diastolic murmurs of aortic incompetence. All the other stigmata of a wide pulse pressure are picked up; Corrigans pulse etc.
The only form of reversing the condition is by means of a cardiac transplant but the problem is that the skeletal changes are so severe.
Gene therapy may be of value as may stem cell therapy. Most patients are put onto anti-cardiac failure therapy which includes Lasix, Slow K 
Digoxin and an ace-inhibitor. Synonyms for the condition are; eccentro-osteochondroplasia, familial osteochondrodystrophy and osteo-
chondrodystrophia deformans. It is also known as Morquio-Ullrich syndrome.



















How pliable is the bicuspid valve? 
H.D. Solomons
Meiring and Partners Pathology Practice, Benoni, South Africa
 
The art of timing on auscultation to see how pliable the mitral valve is in mitral stenosis. By timing the interval between the opening snap 
and the start of the mid-diastolic murmur one can work out how pliable the mitral valve is. The normal time should be about 0,4 seconds. 
One has to be an experienced auscultationist to determine this.
This is useful in mitral stenosis but may also be of value in mixed mitral valve disease. This is best done on auscultation but can also be done 
by means of a phonocardiograph. The closer the interspace between the opening snap and the beginning of the mid-diastolic murmur the 
more pliable the valve.
This gives the cardiothoracic surgeon an indication of who to operate on and the nature of the valve.
Should it be a bjork-shalli, a homograft or a porcine valve? This will ultimately provide the prognosis for the patient and determine whether 
he can avoid cardiac failure or not. So timing is of vital importance in determining how pliable the valve is and the ultimate prognosis of 
the patient. This will determine the morbidity or mortality of the recipient.
Signaling pathways activated in HDL-mediated cardioprotection: is it SAFE or at RISK?
Sarin Somers, Lionel Opie and Sandrine Lecour
Hatter Cardiovascular Research Institute, Faculty of Health Sciences, University of Cape Town, South Africa
Introduction: Sphingosine-1-Phosphate (S1P), a major component of High Density Lipoprotein (HDL), can protect against myocardial 
reperfusion injury but the exact signalling mechanism remains unclear. Recently, two powerful cardioprotective pathways have been 
described, as the RISK pathway (that involves the activation of Akt and FOXO-1) and the SAFE pathway (that involves the activation of 
Signal Transducer and Activator of Transcription-3 (STAT-3)). We propose that these two pathways are involved in S1P induced cardio-
protection.
Methods: Control hearts from wildtype and cardiac defi cient STAT-3 male mice were perfused on a Langendorff apparatus and subjected to 
35min global ischaemia and 45min reperfusion. Alternatively, S1P (10nM) was given at the onset of reperfusion for the fi rst 7min, with/
without STAT-3 and Akt inhibitors, AG490 and Wortmannin (W), respectively.  At the end of the experiment, myocardial infarct size was 
assessed. Additionally, phosphorylated levels of STAT-3, Akt and FOXO-1 were examined by Western Blot analysis after 15min of 
reperfusion in S1P-treated wildtype hearts.
Results: S1P signifi cantly reduced the myocardial infarct size in the wildtype hearts (39.34.4% in control vs 17.33.1% in S1P-treated hearts; 
n≥6; p<0.05) but not in the cardiac defi cient STAT-3 mice (34.72.8% in control vs 34.24.3% in S1P-treated hearts; n≥6; p=ns). Both STAT-3 
and Akt inhibitors abolished the protective effects of S1P (33.73.3% in S1P and AG490 and 36.64.9% in S1P and W; n=6; p<0.05). Levels 
of phosphorylated STAT-3, Akt and FOXO-1 were signifi cantly increased following S1P administration in the wildtype mice (53% STAT-3, 
47% Akt and 41% FOXO-1 greater than control). 
Conclusions: S1P protects against reperfusion injury via the activation of both the SAFE and RISK pathways therefore suggesting a novel 
protective signalling mechanism in HDL induced cardioprotection. These fi ndings may contribute to a better understanding of the cardio-
protective action of HDL and present novel therapeutic opportunities against ischaemic heart disease.    
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The value of cardiac MRI in the diagnosis of Loeffl ers endocarditis: a case report
Johann Steyn*, Sulaiman Moosa#, Niel Hendricks†, Adrzej Okreglicki†, Ernesta Meintjes*, Bongani M. Mayosi†
*Medical Imaging Research Unit, Department of Biomedical Engineering, University of Cape Town, South Africa
#Department of Radiology, Groote Schuur Hospital and University of Cape Town, South Africa  
†Division of Cardiology, Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa  
 
Hypereosinophilic Syndrome is a rare disorder characterised by a persistent eosinophilia of 1,500/mm3 for at least 6 months. It is classifi ed as 
a primary (idiopathic) disorder or secondary to allergies, parasitic infestation, autoimmune disorders, endocrinopathies (eg Addisons), 
myeloproliferative disorders and lymphoma. End organ damage is widespread and affect the heart, brain, bone marrow, skin, lungs, liver and 
gastrointestinal tract. Cardiovascular magnetic resonance can be used to evaluate the nature, extent and implications of hypereosinophilic 
associated myocardial disease.
A 37-year-old woman was admitted with palpitations and worsening dyspnoea. She is known with Graves disease with hypothyroidism 
secondary to radioactive iodine. ECGs showed diffuse subendocardial ischaemic changes and ventricular tachycardia. She was clinically diagnosed 
with non-ST elevation myocardial infarction.  Cardiac Echography showed antero-septal hypokinesia with enhanced endocardial echogenicity. 
Cardiac MRI showed pericardial and pleural effusions, biatrial enlargement, mitral- and tricuspid incompetence and signifi cant obliteration of 
both ventricular apices. The left ventricle had an end diastolic volume of 71,7ml (absol) and ejection fraction of 47%. The delayed enhancement 
showed global endocardial enhancement in a non-ischaemic pattern. Both apices revealed non-enhancing ventricular thrombus with associated 
subendocardial enhancement in the distribution of ventricular injury. The differential diagnosis of non-ischaemic global subendocardial delayed 
enhancement include Amylodosis, Collagen Vascular disease (e.g. Scleroderma) and myocarditis. Associated with bi-apical thrombus, it is classic 
in hypereosinophilic syndrome and Loeffl ers endocarditis. Special investigations showed eosinophilia 3.08 (Normal: 0-0.45) that decreased to 
0.06 over three weeks and platelet count 98 (Normal 178 400 x 109/l).  Bone marrow biopsy revealed a focal increase in marrow eosinophils 
but no morphological evidence of a myeloproliferative disorder or lymphoma. Stools were negative for parasites, but Fasciola serology was 
positive. Endomyocardial biopsy showed mural thrombus, but no eosinophils. The patient received an orthotopic heart transplant. Ex vivo 
histology revealed subendocardial myocyte necrosis, organising endocardial thrombus, infi ltrate of lymphocytes, plasma cells and haemosiderin 
as well as fi brosis and dystrophic calcifi cation. These features support the diagnosis of Loeffl ers endocarditis.
COMMD4: a novel link between cMYBPC-associated HCM, protein traffi cking and turnover?
C.C. Swanepoel, A. Ramburan and J.C. Moolman-Smook 
US/MRC Centre for Molecular and Cellular Biology, Department of Biomedical Sciences, University of Stellenbosch, South Africa
Cardiac myosin binding protein C (cMyBPC) mutations are the second most common cause of hypertrophic cardiomyopathy (HCM), which 
is viewed as a model disease for studying cardiac hypertrophy development. cMYBPC is involved in sarcomeric structure and function and 
also modulates cardiac contractility in a phosphorylation-dependent manner of the MyBPC-motif. In a previous yeast two-hybrid (Y2H) 
library screen, the Copper metabolism MURR1-domain containing protein 4 (COMMD4) was found to bind to the N-terminal of cMyBPC,
 in an interaction similarly dependent on phosphorylation of the MyBPC-motif. Although the functions of COMMD proteins are still unclear, 
it has been linked to copper metabolism as well as the ubiquitin-proteasome pathway (UPS). Interestingly, recent studies have shown that 
the UPS have been implicated in at least MyBPC-derived HCM, whereas dietary copper-depletion has been shown to cause cardiac hyper-
trophy. We therefore set out to investigate the function of COMMD4 by identifying its protein binding partners by Y2H analysis and confi rming 
these interactions via various verifi cation assays.



















A COMMD4 Y2H bait construct was generated and used to screen a cardiac cDNA-library. Putative interactors were identifi ed by direct 
sequencing and analysed using bioinformatics tools. Eight plausible positive interactors were verifi ed via in vitro and in vivo co-immunoprecipi-
tations analysis and 3D live cell fl uorescent colocalisation. The effect of RNAi-mediated COMMD4 knock-down on cMyBPC turnover was 
also investigated.
These plausible interactors yielded novel insights into the role of COMMD4, implicating it in protein traffi cking and turn-over and providing 
support for the link between cMyBPC-related HCM and protein degradation. Therefore, the results to date may shed light on the functioning 
of cMyBPC and also present a greater understanding of its role in the pathogenesis of HCM.
Endovascular covered stent treatment for descending aorta pseudoaneurysm following 
coarctation of the aorta repair in an infant
FF Takawira*, G Sinyangwe*, L Mitchell*, R Mooloo#
*Department of Paediatric Cardiology, Steve Biko Academic Hospital and University of Pretoria, South Africa
#Department of Cardiothoracic Surgery, Steve Biko Academic Hospital and University of Pretoria, South Africa
 
Introduction: Aneurysm development following coarctation of the aorta repair is a rare, but recognised complication. Surgical management 
of these patients is usually associated with a high morbidity and mortality. We describe successful endovascular deployment of a covered 
stent in an infant with a descending aorta pseudoaneurysm.  
Case Report: The infant is one year old and has Downs syndrome.  At six months old he was found to have a complete atrio-ventricular septal 
defect, cooarctation of the aorta and transverse arch hypoplasia for which he had surgical repair. A Gore-Tex graft was used to widen the 
hypoplastic arch and isthmus.
The patient had done well until 12 months of age when he presented in respiratory distress. On examination he weighed 5 kg and appeared 
pale with a haemoglobin of 6 g/dl. He had a right mediastinal shift. There were no signs of congestive cardiac failure. The left lung was dull to 
percussion with decreased air entry. Chest radiography confi rmed complete white out of the left chest and right mediastinal shift with 
the trachea deviated to the right. Echocardiography demonstrated a large extra-cardiac mass in the left chest, with compression of the 
LPA. The mass was fl uid fi lled with evidence of swirling. A CT angiogram demonstrated a large pseudoaneurysm of the descending aorta
just below the origin of the left subclavian artery.  At cardiac catheterisation the large pseudoaneurysm was demonstrated.  A 5 mm x 19 mm 
pre-mounted covered stent was deployed through a 7F sheath and 7F guiding catheter in the descending aorta, straddling the lumen into 
the aneurysm. Surgical evacuation of the aneurysm, which was then a bag of clot was undertaken fi ve days later. The lung re-expanded and 
the infant was discharged from hospital 2 weeks later.  
Discussion: Early or late development of an aortic pseudoaneurysm is a recognised complication following coarctation of the aorta repair. 
It is more common after patch augmentation of the aorta than after end to end anastomosis. It is often seen in patients with aortic arch 
hypoplasia. It has also been described more often following balloon dilatation of native coarctation of the AO. Surgical intervention has 
traditional been used to manage these patients. Endovascular treatment with stents has been performed in adults and older children, but 
has not been described in infants. This approach was selected as the least risky in our patient and proved a major success. The challenges 
include the large femoral artery sheath required to deploy the stent in a small infant. There is also a limit to the size of stent one can deploy, 
leaving the need for future intervention as the patient grows. 
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Clinical characteristics and outcome of lone atrial fi brillation: the Groote Schuur Hospital 
experience
V. Thomas, S. Schulein, V. Khanyi, A. Okreglicki, R.N. Scott Millar and B.M. Mayosi
Cardiac Clinic, Department of Internal Medicine, Groote Schuur Hospital and University of Cape Town, South Africa 
Introduction: Atrial fi brillation (AF) is a common arrhythmia. The classical risk factors are well known. When AF represents an electro-
physiological phenomenon in structurally normal hearts, it is termed lone AF. There are currently no studies to describe the clinical charac-
teristics and outcomes of patients with lone AF in Africa.
Methods: A retrospective descriptive study in which 300 medical records of patients with AF at the GSH Cardiac Clinic were reviewed 
(1992-2006). Clinical data was interrogated to exclude identifi able causes of AF. Information on clinical characteristics and outcomes were 
entered into a data-entry form. Baseline descriptive statistics were expressed as means and range for continuous variables, and counts 
with percentages for categorical variables. 
Results: Fifty three patients had lone AF, with a mean follow-up time of 5.8 years. Males comprised 58% (n=31) and females 42% (n=22). 
The mean age for males was 45; no males being older than 65 at diagnosis. The mean age of females was 58.6. Fifty seven percent (n=30) 
were white, 30% (n=16) were mixed race, 7% (n=4) were black and 6% (n=3) were unspecifi ed. Forty seven percent (n=25) had normal 
weight, 36% (n=19) were overweight and 17% (n=9) were unspecifi ed. Sixty two percent (n=33) had paroxysmal AF, 38% (n=20) had 
chronic AF and 13% (n=7) progressed from paroxysmal to chronic AF. Subsets of lone AF included concomitant atrial fl utter (15%) (n=8) 
and sick sinus syndrome (13%)(n=7). Presenting complaints were palpitations (73%), dizziness (66%), dyspnoea (46%), near blackouts (41%), 
chest pain (22%) and fatigue (22%). Triggers included exercise (27%) and alcohol (17%). Complications included stroke (9%)(n=5), 
tachycardia-related cardiomyopathy (24.5%)(n=13). No mortalities were recorded. Fifty seven percent (n=30) were on betablockers, 23%
(n=12) progressed onto amiodorone, 13% (n=7) had radiofrequency ablations. Nine percent (n=5) had atrioventricular nodal ablations 
with permanent pacemaker insertion. Sixty four percent (n=34) were on warfarin and 23% (n=12) on aspirin for prevention of thrombo-
embolism. Nine percent (n=3) had bleeding complications while on Warfarin.
Conclusion: Ione AF is a relatively common condition with a preponderence to white, thin, middle-aged males. There are subsets of lone 
AF. The symptoms can be debilitating. Complications include tachycardia-related cardiomyopathy and thromboembolism. No mortality 
was recorded. Rate control and appropriate anticoagulation are the cornerstones of patient management.
Delayed mortality in peripartum cardiomyopathy indicates need for long-term follow up
K. Tibazarwa†, K. Sliwa*, O. Forster*, E. Libhaber*, A. Becker*, A. Yip* and D. Hilfi ker-Kleiner#
* Soweto Cardiovascular Research Unit, Department of Cardiology, Chris Hani Baragwanath Hospital, University of the Witwatersrand, 
Johannesburg, South Africa
#Medizinische Hochschule Hannover, Department of Cardiology and Angiology, Hannover, Germany
†Groote Schuur Hospital, University of Cape Town, South Africa
Background: Peripartum cardiomyopathy (PPCM) is a rare form of cardiomyopathy with heterogeneous presentation around the world 
occurring in women between 1 month antepartum and 5 months postpartum. It carries a substantial risk of mortality within the fi rst 6 
months after diagnosis but few studies have outlined prospective long-term morbidity and mortality. The aim of this study is to assess long-
term clinical outcome and mortality over a 2-year period in an African cohort.
Methods: Prospective, single centre study of eighty consecutive women with PPCM enrolled at diagnosis over a period of 2 years. Patients 
were started on standard heart failure therapy (ACE-inhibitors, beta-blockers, diuretics) and detailed assessments, including echocardiography, 
were made at 6-month intervals for 24 months in surviving cases.



















Results:  At baseline, the mean age of this cohort was 29.9 7.4 years, 38% were in their fi rst pregnancy and 34% of patients were co-
infected with HIV. Overall, 89% patients presented in NYHA functional class III-IV at baseline and mean left ventricular ejection fraction 
(LVEF) was 309%. During the 2-year study period, 4 patients were lost to follow-up, 9 moved to remote areas, and 7 had a subsequent 
pregnancy, predisposing them to additional myocardial risk. Within the entire 2 year period, 24 women (30%) died. The mortality rate at 
6 months was 10% (8 of 80), beyond 6 months additional 16 of 69 (23%) patients died despite apparent recovery of left ventricular 
function. In the remaining cases, mean LVEF was:  44 11% at 6 months, 46 13% at 12 months and 50 14% at 24 months follow up, 
respectively. No difference in cardiac function and mortality were observed between PPCM patients with or without HIV co-infection. 
Conclusion: Overall the prognosis in this African cohort was poor confi rming the high mortality rate of PPCM. A novel and somehow 
unexpected fi nding of this study is the high mortality rate in PPCM occurring beyond 6 months, which seems independent from HIV 
infection. This fi nding strongly suggests the need for long-term clinical follow-up including risk assessment of arrhythmic death.
Using protein-protein interactions to identify modifi er genes of cardiac disease
G.M. Uys*, A. Ramburan*, B. Loos#, M. Revera†, A. Goosen**, P.A. Brink** and J.C. Moolman-Smook* 
*US/MRC Centre for Molecular and Cellular Biology, Department of Biomedical Sciences, University of Stellenbosch, South Africa
#Central Analytical Facility, Department of Physiology, University of Stellenbosch, South Africa
†Department of Cardiology, IRCCS San Matteo Hospital, Pavia, Italy
**Department of Medicine, Faculty of Health Sciences, University of Stellenbosch, South Africa
 
In order to identify novel modifi er genes of cardiac disease, our laboratory uses a protein-protein interaction approach to defi ne compo-
nents of molecular pathways involved in these conditions. Using yeast-two-hybrid (Y2H) library screening, novel interactors of a protein 
known to be involved in the particular disease can be identifi ed, and these proteins themselves can then be further tested at a genetic level 
to determine their role as potential modifi er genes.
Cardiac contractility is regulated by dynamic phosphorylation of sarcomeric proteins by kinases such as cAMP-activated protein kinase A 
(PKA) which is anchored close to its targets by A-kinase anchoring proteins (AKAPs) to control phosphorylation. Cardiac Myosin Binding 
Protein-C (cMyBPC) and cardiac troponin I (cTNI) are hypertrophic cardiomyopathy (HCM)-causing sarcomeric proteins which regulate 
contractility in response to PKA phosphorylation. We identifi ed a phosphodiesterase4D-interacting protein-like ligand of the N-terminal of 
cMyBPC via Y2H. This protein is also known as myomegalin. Because AKAPs sometimes anchor both PKA and phosphodiesterases, 
we hypothesized that myomegalin acts as an AKAP, and tested this by Y2H analyses.
The myomegalin cDNA was cloned into a bait vector, which was directly assessed for interaction with two distinct PKA regulatory-
subunit preys. This bait was also used to screen a cardiac cDNA library for novel myomegalin interactors, and the prey clones sequenced to 
determine their identity. 
Myomegalin bound both PKA regulatory subunits as well as with other cardiac proteins that are PKA targets, including cTNI. Thus, myo-
megalin acts as an AKAP in the phosphorylation of sarcomeric proteins involved in the regulation of cardiac contractility. 
The myomegalin (MMGL) and both PKA regulatory subunit genes (PRKAR1A and PRKAR2A) were then tested as potential modifi er genes 
by screening a panel of 353 individuals including genetically and clinically affected plus unaffected HCM individuals for the presence or 
absence of all three HCM founder mutations. Individuals genotypes were determined by subjecting the DNA samples to TaqMan allelic 
discrimination technology using ABI TaqMan Validated SNP Genotyping Assays. Statistical analysis using quantitative transmission disequi-
librium testing (QTDT) was performed to see whether the difference in genotype have an effect on HCM phenotype. One variant in 
MMGL (rs1664005) showed strong association with clinical hypertrophy traits, including left ventricular mass, maximal interventricular 
septum thickness, maximal posterior wall thickness as well as composite scores. Two variants in PRKAR1A (rs11651687 and rs3785906) 
also showed strong association with numerous clinical hypertrophy traits. This study therefore gave statistical evidence that these three variants 
in these two genes may act as modifi ers of the HCM phenotype.
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Protective effect of red palm oil against ischaemia/ reperfusion in isolated perfused rat heart
J. van Rooyen, D. Bester, A.J. Esterhuyse, E.F. du Toit, T. Csont, K. Kupai, P. Ferdinandy and A.M. Engelbrecht 
Department of Biomedical Sciences, Cape Peninsula University of Technology, South Africa
Purpose: The formation of harmful reactive oxygen species (ROS) is associated with several pathological conditions and contributes to 
ischaemia/reperfusion injury. We have previously shown that red palm oil protects against the consequences of ischaemia/reperfusion 
injury. The detailed mechanism of this protection is still unresolved. We investigated whether RPO supplementation could protect against 
ischaemia/reperfusion injury in the isolated perfused rat heart and to elucidate a possible regulatory mechanism associated with the 
regulators of the protective Akt pathway.
Methods: Wistar rats were fed a standard rat chow diet for 4 weeks with or without RPO. Hearts were excised and mounted on a 
Langendorff perfusion apparatus. Reperfusion mechanical function recovery was measured after 25 min of global ischaemia. Hearts were 
freezed clamped at 10 min into reperfusion to investigate Akt and its regulators. In a second protocol wortmannin was added to the 
perfusion fl uid to inhibit PI-3 Kinase. 
Results: Hearts supplemented with RPO showed signifi cantly improved rate pressure product recoveries independent of the presence of 
wortmannin (93.46 5.24% vs 65.50 6.25%, p<0.05). Biochemical results showed that wortmannin successfully inhibited PI-3 Kinase. 
However, Akt was signifi cantly phosphorylated despite the inhibition of PI-3-kinase. RPO also caused signifi cant increases in ERK 44 and 
phospho-ERK 44 in RPO groups, with or without wortmannin.
Conclusions: Our results show that RPO protected successfully against the consequences of ischaemia/reperfusion. Akt was phosphorylated 
despite the inhibition of PI-3 Kinase. This argues for and PI-3 Kinase independent phosphorylation of the pro-survival Akt pathway. Both the 
Akt and ERK pathways may be involved in protection.
Protein phosphatase 2A is not involved in myocardial ischaemia/reperfusion injury... or is it?
Derick van Vuuren, Corli Westcott and Amanda Lochner
Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, South Africa
Research into cardio-protective interventions (such as postconditioning) has emphatically demonstrated the involvement of phosphorylation-
mediated signalling pathways in myocardial ischaemia/reperfusion (I/R) injury. Although the kinases have received much attention, the 
dephosphorylation modulation of these pathways (regulated by the phosphatases) are under-explored.  We aimed to investigate the partici-
pation of a major serine/threonine phosphatase, Protein Phosphatase 2A (PP2A), in the events associated with I/R.
The isolated working rat heart model was used to determine the effects of the administration of a PP2A inhibitor (okadaic acid (OA); 
10 nM a PP2A specifi c concentration), or activator (the A1 agonist 2-chloro-N6-cyclopentyladenosine (CCPA); 0.5 M), or a combination of 
the two for 10 minutes directly prior to an index ischaemia, or in the fi nal 5 minutes of ischaemia and the fi rst 10 minutes of reperfusion. 
An index ischaemia of 35 minutes regional ischaemia (RI; at 36.5 C) was applied to determine infarct size (IFS; expressed as percentage of 
area at risk), while 20 minutes global ischaemia (GI; 36.5 C) was used to investigate functional recovery. Hearts were freeze-clamped at 
different time-intervals in the last half of GI and the fi rst 10 minutes of reperfusion to assess the cellular distribution and modifi cation of 
the PP2A A (scaffolding)- and C (catalytic)-subunits, using Western blotting techniques.
Inhibition of PP2A with OA either before and/or after RI failed to elicit any effect on IFS relative to control. CCPA administration as a 
pretreatment however reduced I/R injury, while reperfusion administration abrogated damage (pretreatment: 29.833.06%; reperfusion 
treatment: 57.573.95 vs control: 40.242.33%; P<0.05). Co-administration with OA did not abolish these effects (pretreatment: 32.476.91%, 



















and reperfusion treatment: 44.226.29%). Preliminary Western blotting data however indicate that both the C- and A-subunits translocate 
between cellular fractions, while the C-subunit is modifi ed during ischaemia and initial reperfusion.
Although A1-stimulation infl uenced the extent of I/R injury, PP2A inhibition failed to implicate PP2A in the events associated with I/R. 
In contrast to this, assessment of PP2A location and modifi cation revealed that PP2A undergoes cellular translocation and modifi cation 
during I/R. It is however still unknown whether these cellular changes are the consequence of I/R injury, or actively mediating I/R response. 
Organ donation and paediatric cardiac transplantation in South Africa
Susan Vosloo
Christiaan Barnard Memorial Hospital, Cape Town, South Africa
South Africa has one of the lowest rates of successful organ donation compared to other countries offering transplantation. In addition, 
signifi cant diversity exists between different regions in SA regarding population composition, mortality rates, causes of death, life-
expectancy and donor referrals, as well as the reasons for non-procurement of potential donors.
The last 2 decades saw transplant services reducing in State institutions, with increased delivery of such needs being provided in the 
private sector.  Despite this, only 40% of patients referred had the procedure.
Worldwide and locally, pediatric patients constitute up to 20% of all cardiac transplantation procedures done annually. Operative mortality, 
as reported by the ISHLT is around 10%, with 1 year survival of over 80% and 5 year survival 70%.
At Christiaan Barnard Memorial Hospital to date over 150 cardiac transplantation procedures had been done. Operative mortality is 
<5%, with 1 and 5 year survival rates comparing favorably with worldwide fi gures. 
Details on the paediatric / congenital group, consisting of 20 patients, will be presented. Of those, half underwent surgery for congenital 
heart defects, not amenable to conventional surgical correction. 
Review of our approach in mediastinal abscess caused by osopharyngeal infections
F.S. Vural, M. Olusoji, A.R. Patel, E. Zigiriadis and F.C. Cardio
Division of Cardiothoracic Surgery, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, 
South Africa
We studied 8 patients with mediastinal abscess caused by oesopharyngeal infections between April 2008 and 2009.
All the patients were operated on after Maxillofacial and ENT surgeons treated the primary source and neck extensions and if necessary 
tracheostomy was performed.  CT chest was obligatory for delineation of extent of disease.  
Two of the patients required right thoracotomy for posterior mediastinal collections of which one of them also had an anterior 
mediastinal collection. Others were treated by parasternal small mediastinotomy (Chamberlain) incisions. Two of them required bilateral 
anterior mediastinal incisions.
After CT control three patients required repeat drainage procedures for new collections.  There was no mortality.  Our conclusion early 
gravity drainage at the most dependent point for mediastinal abscess with good antibiotic cover and repeat CT chest after 3 days in an 
effective approach in highly mortal disease.   
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The quattro valve in rheumatic mitral valve disease: a 10 year follow up
M. Wasiak, P. Manga and A. Patel
Department of Cardiology & Cardiothoracic Surgery, CM Johannesburg Academic Hospital, University of Witwatersrand, Johannesburg, 
South Africa
 
Background & aims: There remains a need for durable bioprosthetic valves in developing countries where monitoring of anticoagulation is 
still problematic. The study aim was to assess the long term outcome of mitral valve replacement with a stentless bovine pericardial quad-
ricuspid (Quattro) valve, which maintains mitral annular-papillary continuity. The study was conducted in relatively young patients with 
isolated severe rheumatic heart disease. 
Methods: Since 1996 the Quattro valve had been implanted in 48 patients. The mean age was 34-13 yrs (34% aged < 25 yrs). All had signi-
fi cant rheumatic mitral valve disease and all patients were symptomatic with the majority (40) in NYHA class III or IV. Patients were 
followed-up at 6 monthly to yearly intervals. At follow-up visits, clinical and echocardiographic evaluations were done in each patient. 
Results: At a mean follow up of 10 0.5 years, the overall mortality was 20.8% (10 deaths). 14 patients have been lost to follow up. 
Of the remaining patients who returned for regular follow-up, 6 patients have had repeat mitral valve replacement for severe valve 
degeneration at a mean interval of 7.3 years after the initial Quattro valve implantation. Five of the 6 patients had rupture of anterior 
leafl et resulting in severe mitral regurgitation. There have been 2 patients with infective endocarditis both requiring valve replacement. 
Thromboembolism or clinically overt haemolysis has not occurred. Serial echocardiographic data were available in 18 patients at the mean 
10 year follow-up interval. Fourteen of these patients have developed moderate to severe valve degeneration. Six have moderate valve 
degeneration. Eight patients have severe valve degeneration and require repeat valve replacement. Only 4 patients remain asymptomatic 
with mild valve degeneration.
Conclusion: Long term results after Quattro valve implantation in a relatively young population has shown poor long term durability. 
There remains a need for more durable bioprosthetic valve types in a younger age group with rheumatic mitral valve disease.
Rheumatic heart disease: the quest for new answers to age-old questions
Liesl Zühlke
Western Cape Pediatrics Cardiac Services, Red Cross and Tygerberg Hospitals, Cape Town, South Africa
At the beginning of the twentieth century, Rheumatic Heart Disease (RHD) was a huge public health burden worldwide. In fact until the 
1960s, it remained a leading cause of death in children. Although the disease has waned signifi cantly in the developed world, 
it continues to reign rampant in the developing world. Conservative estimates report 470 000 new cases of rheumatic fever and 233 000 
deaths attributable to rheumatic fever or rheumatic heart disease each year, almost all of which are occurring in developing countries. 
These numbers demand a new approach to this disease. 
The advent of screening for asymptomatic disease ushered in by the development of sensitive hand-held echo machines has raised an 
important issue: that of the signifi cance of subclinical disease. Screening criteria have to address the minor changes representing rheumatic 
valve damage in its earliest stages. Screening criteria defi ned in a surveillance study conducted in Cape Town separate these into possible, 
probable and defi nite with only defi nites referred for secondary prophylaxis. All participants in the study are undergoing careful follow-up
to determine the long-term course of asymptomatic disease.
Confi rmed cases of RHD in children aged 5-15 years represents only 15-20% of all the cases in a population. Focusing on this vulnerable 
group especially in the developing world is of value in assessing the burden of disease. The most effective way to manage this disease is 
delivering secondary prophylaxis within a strictly controlled register. The soon-to-be-launched Global Registry Initiative provides a unique 
opportunity to both assess the burden of disease while simultaneously managing patients with established disease.
It is 33 years since the remarkable study by Barlow et al highlighted in this conference yet critical questions still remain regarding this age-
old disease. We present our quest for answers using new approaches and strongly invite all practitioners dealing with this disease to join 
the Global registry Initiative. 
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